##	TAG	<div1>
##	TAG	<head>
##	TAG	<name>
1	TOK	Randomised	BOS	Randomised\N46
##	TAG	</name>
2	TOK	placebo		placebo\N5S
---	DLI	-		=\DELIM
3	TOK	controlled		control\VMC----
4	TOK	trial		trial\N5S
5	TOK	of		of\P
6	TOK	ritonavir		ritonavir\N5S
7	TOK	in		in\P
8	TOK	advanced		advance\VMC----
##	TAG	<name>
9	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
10	TOK	1		1\X
##	TAG	</num>
11	TOK	disease	EOS	disease\N5S
##	TAG	</head>
##	TAG	<head>
13	TOK	Introduction	BOS	introduction\N5S
tf	TOK		EOS	=\DELS
##	TAG	</head>
##	TAG	<p>
##	TAG	<s>
15	TOK	Zidovudine	BOS	zidovudine\N5S
16	TOK	was		be\V6F-A66
17	TOK	the		the\AT---6
18	TOK	first		first\MOS
19	TOK	antiretroviral		antiretroviral\JA
20	TOK	treatment		treatment\N5S
21	TOK	shown		show\VMC----
22	TOK	to		to\P
23	TOK	lower		lower\VMI----
24	TOK	the		the\AT---6
25	TOK	rate		rate\N5S
26	TOK	of		of\P
##	TAG	<name>
27	TOK	AIDS		AIDS\N46
##	TAG	</name>
---	DLE	-		=\DELIM
28	TOK	related		relate\VMC----
29	TOK	death		death\N5S
30	TOK	significantly		significantly\DGA7
31	TOK	in		in\P
32	TOK	a		a\AI---S
33	TOK	placebo		placebo\N5S
---	DLI	-		=\DELIM
34	TOK	controlled		control\VMC----
35	TOK	trial		trial\N5S
36	TOK	of		of\P
37	TOK	patients		patient\N5P
38	TOK	with		with\P
39	TOK	advanced		advance\VMC----
##	TAG	<name>
40	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
41	TOK	disease		disease\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
42	TOK	Subsequent	BOS	subsequent\JA
43	TOK	placebo		placebo\N5S
---	DLI	-		=\DELIM
44	TOK	controlled		control\VMC----
45	TOK	clinical		clinical\JA
46	TOK	trials		trial\N5P
47	TOK	have		have\V6F6R66
48	TOK	shown		show\VMC----
49	TOK	its		its\APS3N6
50	TOK	clinical		clinical\JA
51	TOK	effectiveness		effectiveness\N5S
52	TOK	in		in\P
53	TOK	the		the\AT---6
54	TOK	prevention		prevention\N5S
55	TOK	of		of\P
56	TOK	minor		minor\JA
57	TOK	opportunistic		opportunistic\JA
58	TOK	infections		infection\N5P
59	TOK	in		in\P
60	TOK	patients		patient\N5P
61	TOK	with		with\P
62	TOK	moderate		moderate\JA
63	TOK	immunodeficiency		immunodeficiency\N5S
64	TOK	and		and\CC
65	TOK	in		in\P
66	TOK	those		that\RDP3N-
67	TOK	with		with\P
68	TOK	primary		primary\JA
##	TAG	<name>
69	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
70	TOK	1		1\X
##	TAG	</num>
71	TOK	infection		infection\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
72	TOK	Compared	BOS	compare\VMC----
73	TOK	with		with\P
74	TOK	zidovudine		zidovudine\N5S
75	TOK	monotherapy		monotherapy\N5P
---	DLD	,		=\DELIM
76	TOK	other		other\JA
77	TOK	nucleoside		nucleoside\N5S
78	TOK	analogues		analogue\N5P
---	DLE	(		=\DELIM
79	TOK	alone		alone\JA
80	TOK	or		or\CC
81	TOK	in		in\P
82	TOK	combination		combination\N5S
83	TOK	with		with\P
84	TOK	zidovudine		zidovudine\N5S
---	DLD	)		=\DELIM
85	TOK	have		have\V6F6R66
86	TOK	delayed		delay\VMC----
87	TOK	the		the\AT---6
88	TOK	onset		onset\N5S
89	TOK	of		of\P
##	TAG	<name>
90	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
91	TOK	1		1\X
##	TAG	</num>
92	TOK	disease		disease\N5S
93	TOK	progression		progression\N5S
94	TOK	or		or\CC
95	TOK	death		death\N5S
96	TOK	in		in\P
97	TOK	patients		patient\N5P
98	TOK	with		with\P
99	TOK	moderate		moderate\JA
100	TOK	immunodeficiency		immunodeficiency\N5S
101	TOK	in		in\P
102	TOK	relatively		relatively\DGA7
103	TOK	long		long\JA
104	TOK	clinical		clinical\JA
105	TOK	trials		trial\N5P
---	DLD	,		=\DELIM
106	TOK	particularly		particularly\DGA7
107	TOK	as		as\P
108	TOK	initial		initial\JA
109	TOK	therapy		therapy\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
110	TOK	Ritonavir	BOS	ritonavir\N5S
---	DLE	(		=\DELIM
##	TAG	<name>
111	TOK	Norvir		Norvir\N46
##	TAG	</name>
---	DLE	,		=\DELIM
##	TAG	<name>
112	TOK	Abbott Laboratories		Abbott_Laboratories\N46
##	TAG	</name>
---	DLE	,		=\DELIM
##	TAG	<name>
113	TOK	IL		IL\N46
##	TAG	</name>
---	DLE	,		=\DELIM
##	TAG	<name>
114	TOK	USA		USA\N46
##	TAG	</name>
---	DLE	)		=\DELIM
115	TOK	is		be\V6FDRS3
116	TOK	a		a\AI---S
117	TOK	specific		specific\JA
118	TOK	and		and\CC
119	TOK	potent		potent\JA
120	TOK	inhibitor		inhibitor\N5S
121	TOK	of		of\P
##	TAG	<name>
122	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
123	TOK	1		1\X
##	TAG	</num>
124	TOK	aspartyl		aspartyl\N5S
125	TOK	protease		protease\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
126	TOK	The	BOS	the\AT---6
127	TOK	drug		drug\N5S
128	TOK	has		have\V6FDRS3
129	TOK	high		high\JA
130	TOK	oral		oral\JA
131	TOK	bioavailability		bioavailability\N5S
132	TOK	and		and\CC
133	TOK	a		a\AI---S
134	TOK	long		long\JA
135	TOK	plasma		plasma\N5S
136	TOK	half		half\N5S
---	DLI	-		=\DELIM
137	TOK	life		life\N5S
---	DLD	,		=\DELIM
138	TOK	which		which\RW63N-
139	TOK	allows		allow\VMFDRS3
140	TOK	twice		twice\DGA7
---	DLI	-		=\DELIM
141	TOK	daily		daily\JA
142	TOK	dosing		dose\VMG----
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
143	TOK	Compared	BOS	compare\VMC----
144	TOK	with		with\P
145	TOK	nucleoside		nucleoside\N5S
146	TOK	analogues		analogue\N5P
---	DLD	,		=\DELIM
147	TOK	ritonavir		ritonavir\N5S
148	TOK	has		have\V6FDRS3
149	TOK	a		a\AI---S
150	TOK	more		more\DDC7
151	TOK	potent		potent\JA
152	TOK	and		and\CC
153	TOK	sustained		sustain\VMC----
154	TOK	effect		effect\N5S
155	TOK	on		on\P
156	TOK	plasma		plasma\N5S
157	TOK	viraemia		viraemia\N5S
---	DLD	,		=\DELIM
158	TOK	cellular		cellular\JA
##	TAG	<name>
159	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
160	TOK	1		1\X
##	TAG	</num>
---	DLE	-		=\DELIM
161	TOK	infection		infection\N5S
162	TOK	loads		load\N5P
---	DLD	,		=\DELIM
163	TOK	and		and\CC
164	TOK	lymphocyte		lymphocyte\N5S
165	TOK	immunophenotype		immunophenotype\N5S
166	TOK	subsets		subset\N5P
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
167	TOK	In	BOS	in\P
168	TOK	clinical		clinical\JA
169	TOK	trials		trial\N5P
170	TOK	on		on\P
##	TAG	<name>
171	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
172	TOK	1		1\X
##	TAG	</num>
---	DLE	,		=\DELIM
173	TOK	some		some\DGA7
174	TOK	surrogate		surrogate\VMF6R66
---	DLI	-		=\DELIM
175	TOK	marker		marker\N5S
176	TOK	responses		response\N5P
177	TOK	predict		predict\VMF6R66
178	TOK	clinical		clinical\JA
179	TOK	efficacy		efficacy\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
180	TOK	However	BOS	however\DGA7
---	DLD	,		=\DELIM
181	TOK	their		their\APP3N6
182	TOK	usefulness		usefulness\N5S
183	TOK	in		in\P
184	TOK	assessment		assessment\N5S
185	TOK	of		of\P
186	TOK	protease		protease\N5S
---	DLI	-		=\DELIM
187	TOK	inhibitor		inhibitor\N5S
188	TOK	therapy		therapy\N5S
189	TOK	is		be\V6FDRS3
190	TOK	not		not\DGA7
191	TOK	clear		clear\JA
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
192	TOK	Therefore	BOS	therefore\DGA7
---	DLD	,		=\DELIM
193	TOK	this		this\AD---S
194	TOK	study		study\N5S
195	TOK	was		be\V6F-A66
196	TOK	designed		design\VMC----
197	TOK	as		as\P
198	TOK	a		a\AI---S
199	TOK	simple		simple\JA
200	TOK	large		large\JA
---	DLI	-		=\DELIM
201	TOK	scale		scale\N5S
202	TOK	clinical		clinical\JA
203	TOK	trial		trial\N5S
204	TOK	to		to\P
205	TOK	investigate		investigate\VMI----
206	TOK	rapidly		rapidly\DGA7
---	DLD	,		=\DELIM
207	TOK	in		in\P
208	TOK	a		a\AI---S
209	TOK	specific		specific\JA
210	TOK	subpopulation		subpopulation\N5S
211	TOK	of		of\P
212	TOK	patients		patient\N5P
213	TOK	with		with\P
##	TAG	<name>
214	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
215	TOK	1		1\X
##	TAG	</num>
216	TOK	disease		disease\N5S
---	DLE	(		=\DELIM
##	TAG	<name>
217	TOK	CD4		CD4\N46
##	TAG	</name>
---	DLE	-		=\DELIM
218	TOK	lymphocyte		lymphocyte\N5S
219	TOK	counts		count\N5P
220	TOK	xxx		noanat\W
---	DLE	)		=\DELIM
---	DLD	,		=\DELIM
221	TOK	the		the\AT---6
222	TOK	safety		safety\N5S
223	TOK	and		and\CC
224	TOK	clinical		clinical\JA
225	TOK	efficacy		efficacy\N5S
226	TOK	of		of\P
227	TOK	ritonavir		ritonavir\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
228	TOK	These	BOS	this\AD---P
229	TOK	results		result\N5P
230	TOK	might		may\VOFDR66
231	TOK	be		be\VMI----
232	TOK	generalisable		generalisable\JA
233	TOK	to		to\P
234	TOK	a		a\AI---S
235	TOK	larger		large\JC
236	TOK	population		population\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<head>
237	TOK	Methods	BOS	method\N5P
tf	TOK		EOS	=\DELS
##	TAG	</head>
##	TAG	<p>
##	TAG	<s>
239	TOK	The	BOS	the\AT---6
240	TOK	primary		primary\JA
241	TOK	objective		objective\N5S
242	TOK	of		of\P
243	TOK	this		this\AD---S
244	TOK	randomised		randomised\JA
---	DLD	,		=\DELIM
245	TOK	double		double\AG---6
---	DLI	-		=\DELIM
246	TOK	blind		blind\JA
---	DLD	,		=\DELIM
247	TOK	placebo		placebo\N5S
---	DLI	-		=\DELIM
248	TOK	controlled		control\VMC----
---	DLD	,		=\DELIM
249	TOK	multicentre		multicentre\N5S
250	TOK	trial		trial\N5S
251	TOK	was		be\V6F-A66
252	TOK	to		to\P
253	TOK	test		test\VMI----
254	TOK	the		the\AT---6
255	TOK	effectiveness		effectiveness\N5S
256	TOK	of		of\P
257	TOK	ritonavir		ritonavir\N5S
258	TOK	oral		oral\JA
259	TOK	solution		solution\N5S
---	DLE	(		=\DELIM
##	TAG	<num>
260	TOK	600		600\X
##	TAG	</num>
261	TOK	mg		mg\N5S
262	TOK	twice		twice\DGA7
263	TOK	daily		daily\JA
---	DLD	)		=\DELIM
264	TOK	in		in\P
265	TOK	reducing		reduce\VMG----
266	TOK	the		the\AT---6
267	TOK	rate		rate\N5S
268	TOK	of		of\P
269	TOK	death		death\N5S
270	TOK	or		or\CC
271	TOK	any		any\AG---6
272	TOK	new		new\JA
---	DLD	,		=\DELIM
273	TOK	or		or\CC
274	TOK	specified		specify\VMC----
275	TOK	recurrent		recurrent\JA
---	DLD	,		=\DELIM
##	TAG	<name>
276	TOK	AIDS		AIDS\N46
##	TAG	</name>
---	DLE	-		=\DELIM
277	TOK	defining		define\VMG----
278	TOK	illness		illness\N5S
279	TOK	in		in\P
280	TOK	a		a\AI---S
281	TOK	population		population\N5S
282	TOK	of		of\P
##	TAG	<name>
283	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
284	TOK	1		1\X
##	TAG	</num>
---	DLE	-		=\DELIM
285	TOK	infected		infect\VMC----
286	TOK	adults		adult\N5P
287	TOK	with		with\P
##	TAG	<name>
288	TOK	CD4		CD4\N46
##	TAG	</name>
---	DLE	-		=\DELIM
289	TOK	lymphocyte		lymphocyte\N5S
290	TOK	counts		count\N5P
291	TOK	of		of\P
##	TAG	<na type="function">
292	TOK	100/mL		noanat\W
##	TAG	</na>
293	TOK	or		or\CC
294	TOK	less		less\DDC7
---	DLD	,		=\DELIM
295	TOK	while		while\CS
296	TOK	permitting		permit\VMG----
297	TOK	concurrent		concurrent\JA
298	TOK	use		use\N5S
299	TOK	of		of\P
300	TOK	licensed		license\VMC----
301	TOK	anti		anti\JA
---	DLD	-		=\DELIM
##	TAG	<name>
302	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
303	TOK	1		1\X
##	TAG	</num>
304	TOK	therapy		therapy\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
305	TOK	Secondary	BOS	secondary\JA
306	TOK	objectives		objective\N5P
307	TOK	were		be\V6F-A66
308	TOK	to		to\P
309	TOK	assess		assess\VMI----
310	TOK	the		the\AT---6
311	TOK	effect		effect\N5S
312	TOK	of		of\P
313	TOK	ritonavir		ritonavir\N5S
314	TOK	on		on\P
315	TOK	counts		count\N5P
316	TOK	of		of\P
##	TAG	<name>
317	TOK	CD4		CD4\N46
##	TAG	</name>
318	TOK	and		and\CC
##	TAG	<name>
319	TOK	CD8		CD8\N46
##	TAG	</name>
320	TOK	lymphocytes		lymphocyte\N5P
321	TOK	and		and\CC
322	TOK	plasma		plasma\N5S
323	TOK	concentrations		concentration\N5P
324	TOK	of		of\P
##	TAG	<name>
325	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
326	TOK	1		1\X
##	TAG	</num>
##	TAG	<name>
327	TOK	RNA		RNA\N46
##	TAG	</name>
---	DLE	(		=\DELIM
##	TAG	<name>
328	TOK	Roche Amplicor		Roche_Amplicor\N46
##	TAG	</name>
---	DLD	;		=\DELIM
329	TOK	lower		low\JC
330	TOK	limit		limit\N5S
331	TOK	of		of\P
332	TOK	detection		detection\N5S
##	TAG	<num>
333	TOK	200		200\X
##	TAG	</num>
334	TOK	copies		copy\N5P
---	DLE	/		=\DELIM
335	TOK	mL		mL\N5P
---	DLE	)		=\DELIM
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
337	TOK	Plasma	BOS	plasma\N5S
338	TOK	viraemia		viraemia\N5S
339	TOK	response		response\N5S
340	TOK	was		be\V6F-A66
341	TOK	studied		study\VMC----
342	TOK	in		in\P
343	TOK	a		a\AI---S
344	TOK	subset		subset\N5S
345	TOK	of		of\P
346	TOK	patients		patient\N5P
---	DLI	-		=\DELIM
347	TOK	the		the\AT---6
348	TOK	first		first\MOS
##	TAG	<num>
349	TOK	159		159\X
##	TAG	</num>
350	TOK	randomised		randomised\JA
351	TOK	patients		patient\N5P
352	TOK	with		with\P
353	TOK	baseline		baseline\N5S
354	TOK	plasma		plasma\N5S
##	TAG	<name>
355	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
356	TOK	1		1\X
##	TAG	</num>
##	TAG	<name>
357	TOK	RNA		RNA\N46
##	TAG	</name>
358	TOK	concentrations		concentration\N5P
359	TOK	higher		high\JC
360	TOK	than		than\CS
##	TAG	<num>
361	TOK	15		15\X
##	TAG	</num>
##	TAG	<num>
362	TOK	000		000\X
##	TAG	</num>
363	TOK	copies/mL		copies/mL\N5P
---	DLE	(		=\DELIM
364	TOK	antiviral		antiviral\JA
365	TOK	activity		activity\N5S
366	TOK	subset		subset\N5S
---	DLD	)		=\DELIM
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
367	TOK	The	BOS	the\AT---6
368	TOK	study		study\N5S
369	TOK	protocol		protocol\N5S
370	TOK	was		be\V6F-A66
371	TOK	approved		approve\VMC----
372	TOK	by		by\P
373	TOK	the		the\AT---6
374	TOK	appropriate		appropriate\JA
375	TOK	regulatory		regulatory\JA
376	TOK	agencies		agency\N5P
377	TOK	and		and\CC
378	TOK	institutional		institutional\JA
379	TOK	review		review\N5S
380	TOK	boards		board\N5P
381	TOK	of		of\P
382	TOK	the		the\AT---6
383	TOK	participating		participate\VMG----
384	TOK	centres		centre\N5P
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<head>
385	TOK	Patients	BOS	patient\N5P
tf	TOK		EOS	=\DELS
##	TAG	</head>
##	TAG	<p>
##	TAG	<s>
387	TOK	Participants	BOS	participant\N5P
388	TOK	provided		provide\VMC----
389	TOK	written		write\VMC----
390	TOK	informed		inform\VMC----
391	TOK	consent		consent\N5S
392	TOK	before		before\CS
393	TOK	they		they\RPP3NN
394	TOK	underwent		undergo\VMF6A66
395	TOK	any		any\AG---6
396	TOK	screening		screening\N5S
397	TOK	procedures		procedure\N5P
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
398	TOK	Eligible	BOS	eligible\JA
399	TOK	participants		participant\N5P
400	TOK	were		be\V6F-A66
##	TAG	<loc pos="DGA7">
401	TOK	at least		at_least\DGA7
##	TAG	</loc>
##	TAG	<num>
402	TOK	12		12\X
##	TAG	</num>
##	TAG	<loc pos="N5P">
403	TOK	years old		years_old\N5P
##	TAG	</loc>
---	DLE	,		=\DELIM
404	TOK	had		have\V6F6A66
405	TOK	a		a\AI---S
406	TOK	confirmed		confirm\VMC----
407	TOK	serum		serum\N5S
408	TOK	antibody		antibody\N5S
409	TOK	test		test\N5S
410	TOK	for		for\P
##	TAG	<name>
411	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
412	TOK	1		1\X
##	TAG	</num>
---	DLE	,		=\DELIM
413	TOK	a		a\AI---S
##	TAG	<name>
414	TOK	CD4		CD4\N46
##	TAG	</name>
---	DLE	-		=\DELIM
415	TOK	lymphocyte		lymphocyte\N5S
416	TOK	count		count\N5S
417	TOK	of		of\P
##	TAG	<na type="function">
418	TOK	100/mL		noanat\W
##	TAG	</na>
419	TOK	or		or\CC
420	TOK	less		less\DDC7
---	DLD	,		=\DELIM
421	TOK	and		and\CC
422	TOK	had		have\V6F6A66
423	TOK	received		receive\VMC----
##	TAG	<loc pos="DGA7">
424	TOK	at least		at_least\DGA7
##	TAG	</loc>
##	TAG	<num>
425	TOK	9		9\X
##	TAG	</num>
426	TOK	months		month\N5P
427	TOK	of		of\P
428	TOK	therapy		therapy\N5S
429	TOK	with		with\P
##	TAG	<loc pos="DGA7">
430	TOK	at least		at_least\DGA7
##	TAG	</loc>
431	TOK	one		one\MCS
432	TOK	approved		approve\VMF6A66
433	TOK	nucleoside		nucleoside\N5S
---	DLE	(		=\DELIM
434	TOK	zidovudine		zidovudine\N5S
---	DLD	,		=\DELIM
435	TOK	zalcitabine		zalcitabine\N5S
---	DLD	,		=\DELIM
436	TOK	didanosine		didanosine\N5S
---	DLD	,		=\DELIM
437	TOK	or		or\CC
438	TOK	stavudine		stavudine\N5S
---	DLD	)		=\DELIM
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
439	TOK	In	BOS	in\P
440	TOK	addition		addition\N5S
---	DLD	,		=\DELIM
441	TOK	participants		participant\N5P
442	TOK	had		have\V6F6A66
##	TAG	<loc pos="DGA7">
443	TOK	at least		at_least\DGA7
##	TAG	</loc>
##	TAG	<num>
444	TOK	6		6\X
##	TAG	</num>
445	TOK	weeks		week\N5P
446	TOK	of		of\P
447	TOK	stable		stable\JA
448	TOK	therapy		therapy\N5S
449	TOK	up		up\P
450	TOK	to		to\P
451	TOK	baseline		baseline\N5S
452	TOK	with		with\P
453	TOK	a		a\AI---S
##	TAG	<name>
454	TOK	Karnofsky		Karnofsky\N46
##	TAG	</name>
455	TOK	score		score\N56
456	TOK	of		of\P
457	TOK	more		more\DDC7
458	TOK	than		than\CS
##	TAG	<num>
459	TOK	70		70\X
##	TAG	</num>
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
460	TOK	Exclusion	BOS	exclusion\N5S
461	TOK	criteria		criterion\N5P
462	TOK	included		include\VMF6A66
463	TOK	previous		previous\JA
464	TOK	enrolment		enrolment\N5S
465	TOK	in		in\P
466	TOK	this		this\AD---S
467	TOK	study		study\N5S
468	TOK	or		or\CC
469	TOK	another		another\JA
470	TOK	study		study\N5S
471	TOK	of		of\P
472	TOK	an		an\AI---S
##	TAG	<name>
473	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
474	TOK	1		1\X
##	TAG	</num>
475	TOK	protease		protease\N5S
476	TOK	inhibitor		inhibitor\N5S
---	DLD	,		=\DELIM
477	TOK	acute		acute\JA
478	TOK	illness		illness\N5S
---	DLD	,		=\DELIM
479	TOK	predefined		predefined\JA
480	TOK	haematological		haematological\JA
481	TOK	or		or\CC
482	TOK	biochemical		biochemical\JA
483	TOK	abnormality		abnormality\N5S
---	DLD	,		=\DELIM
484	TOK	current		current\JA
485	TOK	treatment		treatment\N5S
486	TOK	with		with\P
487	TOK	more		more\DDC7
488	TOK	than		than\CS
##	TAG	<num>
489	TOK	two		two\X
##	TAG	</num>
490	TOK	nucleoside		nucleoside\N5S
491	TOK	reverse		reverse\JA
---	DLI	-		=\DELIM
492	TOK	transcriptase		transcriptase\N5S
493	TOK	inhibitors		inhibitor\N5P
---	DLD	,		=\DELIM
494	TOK	experimental		experimental\JA
495	TOK	or		or\CC
496	TOK	illicit		illicit\JA
497	TOK	recreational		recreational\JA
498	TOK	drug		drug\N5S
499	TOK	use		use\VMF6R66
---	DLD	,		=\DELIM
500	TOK	treatment		treatment\N5S
501	TOK	with		with\P
502	TOK	specific		specific\JA
503	TOK	contraindicated		contraindicate\VMC----
504	TOK	drugs		drug\N5P
---	DLD	,		=\DELIM
505	TOK	pregnancy		pregnancy\N5S
---	DLD	,		=\DELIM
506	TOK	and		and\CC
507	TOK	breastfeeding		breastfeeding\N5P
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<head>
508	TOK	Endpoints	BOS	endpoint\N5P
tf	TOK		EOS	=\DELS
##	TAG	</head>
##	TAG	<p>
##	TAG	<s>
510	TOK	The	BOS	the\AT---6
511	TOK	primary		primary\JA
512	TOK	outcome		outcome\N5S
513	TOK	measure		measure\N5S
514	TOK	was		be\V6F-A66
515	TOK	the		the\AT---6
516	TOK	time		time\N5S
517	TOK	to		to\P
518	TOK	any		any\AG---6
519	TOK	new		new\JA
##	TAG	<name>
520	TOK	AIDS		AIDS\N46
##	TAG	</name>
521	TOK	defining		define\VMG----
522	TOK	illness		illness\N5S
523	TOK	or		or\CC
524	TOK	death		death\N5S
525	TOK	not		not\DGA7
526	TOK	preceded		precede\VMF6A66
527	TOK	by		by\P
528	TOK	an		an\AI---S
##	TAG	<name>
529	TOK	AIDS		AIDS\N46
##	TAG	</name>
---	DLE	-		=\DELIM
530	TOK	defining		define\VMG----
531	TOK	event		event\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
532	TOK	A	BOS	a\AI---S
533	TOK	new		new\JA
##	TAG	<name>
534	TOK	AIDS		AIDS\N46
##	TAG	</name>
---	DLE	-		=\DELIM
535	TOK	defining		define\VMG----
536	TOK	event		event\N5S
537	TOK	was		be\V6F-A66
538	TOK	any		any\AG---6
539	TOK	clinical		clinical\JA
540	TOK	illness		illness\N5S
541	TOK	specified		specify\VMC----
542	TOK	by		by\P
543	TOK	the		the\AT---6
##	TAG	<name>
544	TOK	US Centers for Disease Control		US_Centers_for_Disease_Control\N46
##	TAG	</name>
545	TOK	and		and\CC
##	TAG	<name>
546	TOK	Prevention		Prevention\N46
##	TAG	</name>
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
547	TOK	The	BOS	the\AT---6
548	TOK	recurrence		recurrence\N5S
549	TOK	of		of\P
550	TOK	pneumocystosis		pneumocystosis\N5S
---	DLD	,		=\DELIM
551	TOK	oesophageal		oesophageal\JA
552	TOK	candidosis		candidosis\N5P
---	DLD	,		=\DELIM
553	TOK	or		or\CC
554	TOK	chronic		chronic\JA
555	TOK	herpetic		herpetic\JA
556	TOK	ulcer		ulcer\N5S
557	TOK	was		be\V6F-A66
558	TOK	also		also\DGA7
559	TOK	included		include\VMC----
560	TOK	as		as\P
561	TOK	a		a\AI---S
562	TOK	primary		primary\JA
563	TOK	outcome		outcome\N5S
---	DLD	,		=\DELIM
564	TOK	but		but\CC
565	TOK	recurrence		recurrence\N5S
566	TOK	or		or\CC
567	TOK	progression		progression\N5S
568	TOK	of		of\P
569	TOK	other		other\JA
570	TOK	events		event\N5P
571	TOK	was		be\V6F-A66
572	TOK	not		not\DGA7
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
573	TOK	A	BOS	a\AI---S
574	TOK	secondary		secondary\JA
575	TOK	primary		primary\JA
576	TOK	outcome		outcome\N5S
577	TOK	measure		measure\VMI----
---	DLD	,		=\DELIM
578	TOK	analysed		analyse\VMC----
579	TOK	separately		separately\DGA7
---	DLD	,		=\DELIM
580	TOK	was		be\V6F-A66
581	TOK	death		death\N5S
582	TOK	from		from\P
583	TOK	any		any\AG---6
584	TOK	cause		cause\VMF6R66
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
585	TOK	Each	BOS	each\AG---S
586	TOK	event		event\N5S
587	TOK	reported		report\VMC----
588	TOK	as		as\P
589	TOK	a		a\AI---S
590	TOK	disease		disease\N5S
591	TOK	outcome		outcome\N5S
592	TOK	was		be\V6F-A66
593	TOK	assessed		assess\VMC----
594	TOK	by		by\P
##	TAG	<num>
595	TOK	two		two\X
##	TAG	</num>
596	TOK	independent		independent\JA
597	TOK	reviewers		reviewer\N5P
---	DLE	(		=\DELIM
##	TAG	<name>
598	TOK	DWC		DWC\N46
##	TAG	</name>
599	TOK	and		and\CC
##	TAG	<name>
600	TOK	SK		SK\N46
##	TAG	</name>
---	DLE	)		=\DELIM
601	TOK	without		without\P
602	TOK	knowledge		knowledge\N5S
603	TOK	of		of\P
604	TOK	treatment		treatment\N5S
605	TOK	allocation		allocation\N5S
606	TOK	and		and\CC
##	TAG	<loc pos="P">
607	TOK	according to		according_to\P
##	TAG	</loc>
608	TOK	predefined		predefined\JA
609	TOK	diagnostic		diagnostic\JA
610	TOK	criteria		criterion\N5P
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
611	TOK	Source	BOS	source\N5S
612	TOK	documentation		documentation\N5S
613	TOK	to		to\P
614	TOK	support		support\VMI----
615	TOK	a		a\AI---S
616	TOK	high		high\JA
617	TOK	degree		degree\N5S
618	TOK	of		of\P
619	TOK	clinical		clinical\JA
620	TOK	confidence		confidence\N5S
621	TOK	was		be\V6F-A66
622	TOK	required		require\VMC----
623	TOK	to		to\P
624	TOK	confirm		confirm\VMI----
625	TOK	each		each\AG---S
626	TOK	event		event\N5S
627	TOK	as		as\P
628	TOK	a		a\AI---S
629	TOK	clinical		clinical\JA
630	TOK	endpoint		endpoint\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<head>
##	TAG	<name>
631	TOK	Randomisation	BOS	Randomisation\N46
##	TAG	</name>
tf	TOK		EOS	=\DELS
##	TAG	</head>
##	TAG	<p>
##	TAG	<s>
633	TOK	Eligible	BOS	eligible\JA
634	TOK	patients		patient\N5P
635	TOK	were		be\V6F-A66
636	TOK	randomly		randomly\DGA7
637	TOK	assigned		assign\VMC----
638	TOK	ritonavir		ritonavir\N5S
---	DLE	(		=\DELIM
##	TAG	<num>
639	TOK	600		600\X
##	TAG	</num>
640	TOK	mg		mg\N5S
641	TOK	in		in\P
642	TOK	a		a\AI---S
643	TOK	liquid		liquid\N5S
644	TOK	oral		oral\JA
645	TOK	solution		solution\N5S
646	TOK	twice		twice\DGA7
647	TOK	daily		daily\JA
---	DLD	)		=\DELIM
648	TOK	or		or\CC
649	TOK	a		a\AI---S
650	TOK	matching		match\VMG----
##	TAG	<foreign lang="LA" pos="N5S">
651	TOK	placebo		placebo\N5S
##	TAG	</foreign>
---	DLE	(		=\DELIM
652	TOK	liquid		liquid\N5S
653	TOK	oral		oral\JA
654	TOK	solution		solution\N5S
655	TOK	twice		twice\DGA7
656	TOK	daily		daily\JA
---	DLD	)		=\DELIM
657	TOK	by		by\P
658	TOK	means		mean\N56
659	TOK	of		of\P
660	TOK	a		a\AI---S
661	TOK	computer		computer\N5S
---	DLI	-		=\DELIM
662	TOK	generated		generate\VMC----
663	TOK	schedule		schedule\VMF6R66
---	DLE	(		=\DELIM
664	TOK	prepared		prepare\VMC----
665	TOK	by		by\P
##	TAG	<name>
666	TOK	Abbott Laboratories		Abbott_Laboratories\N46
##	TAG	</name>
---	DLE	)		=\DELIM
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
667	TOK	The	BOS	the\AT---6
668	TOK	assignment		assignment\N5S
669	TOK	of		of\P
670	TOK	patients		patient\N5P
671	TOK	was		be\V6F-A66
672	TOK	done		do\VMC----
673	TOK	in		in\P
674	TOK	blocks		block\N5P
675	TOK	of		of\P
##	TAG	<num>
676	TOK	four		four\X
##	TAG	</num>
---	DLE	,		=\DELIM
677	TOK	stratified		stratify\VMC----
678	TOK	by		by\P
679	TOK	geographical		geographical\JA
680	TOK	region		region\N5S
---	DLE	(		=\DELIM
##	TAG	<name>
681	TOK	North America		North_America\N46
##	TAG	</name>
---	DLE	,		=\DELIM
##	TAG	<name>
682	TOK	Europe		Europe\N46
##	TAG	</name>
---	DLE	,		=\DELIM
683	TOK	and		and\CC
##	TAG	<name>
684	TOK	Australia		Australia\N46
##	TAG	</name>
---	DLE	)		=\DELIM
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
686	TOK	Allocation	BOS	allocation\N5S
687	TOK	concealment		concealment\N5S
688	TOK	was		be\V6F-A66
689	TOK	ensured		ensure\VMC----
690	TOK	by		by\P
691	TOK	the		the\AT---6
692	TOK	use		use\N5S
693	TOK	of		of\P
694	TOK	an		an\AI---S
695	TOK	automated		automate\VMC----
696	TOK	voice		voice\N5S
---	DLI	-		=\DELIM
697	TOK	response		response\N5S
698	TOK	system		system\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<head>
699	TOK	Procedures	BOS	procedure\N5P
tf	TOK		EOS	=\DELS
##	TAG	</head>
##	TAG	<p>
##	TAG	<s>
701	TOK	Patients	BOS	patient\N5P
702	TOK	who		who\RW63N-
703	TOK	gave		give\VMF6A66
704	TOK	informed		inform\VMC----
705	TOK	consent		consent\N5S
706	TOK	were		be\V6F-A66
707	TOK	screened		screen\VMC----
708	TOK	by		by\P
709	TOK	a		a\AI---S
710	TOK	complete		complete\JA
711	TOK	medical		medical\JA
712	TOK	history		history\N5S
713	TOK	and		and\CC
714	TOK	a		a\AI---S
715	TOK	review		review\N5S
716	TOK	of		of\P
717	TOK	concurrent		concurrent\JA
718	TOK	medications		medication\N5P
---	DLD	,		=\DELIM
719	TOK	a		a\AI---S
720	TOK	complete		complete\JA
721	TOK	physical		physical\JA
722	TOK	examination		examination\N5S
---	DLD	,		=\DELIM
723	TOK	electrocardiography		electrocardiography\N5S
---	DLD	,		=\DELIM
724	TOK	chest		chest\N5S
725	TOK	radiography		radiography\N5S
---	DLD	,		=\DELIM
726	TOK	counts		count\N5P
727	TOK	of		of\P
##	TAG	<name>
728	TOK	CD4		CD4\N46
##	TAG	</name>
729	TOK	and		and\CC
##	TAG	<name>
730	TOK	CD8		CD8\N46
##	TAG	</name>
731	TOK	lymphocytes		lymphocyte\N5P
---	DLD	,		=\DELIM
732	TOK	and		and\CC
733	TOK	routine		routine\JA
734	TOK	haematological		haematological\JA
735	TOK	and		and\CC
736	TOK	biochemical		biochemical\JA
737	TOK	laboratory		laboratory\N5S
738	TOK	studies		study\N5P
739	TOK	during		during\P
740	TOK	a		a\AI---S
##	TAG	<num>
741	TOK	28		28\X
##	TAG	</num>
---	DLE	-		=\DELIM
742	TOK	day		day\N5S
743	TOK	period		period\N5S
744	TOK	before		before\P
745	TOK	randomisation		randomisation\N5P
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
746	TOK	Baseline	BOS	baseline\N5S
747	TOK	counts		count\N5P
748	TOK	of		of\P
##	TAG	<name>
749	TOK	CD4		CD4\N46
##	TAG	</name>
750	TOK	and		and\CC
##	TAG	<name>
751	TOK	CD8		CD8\N46
##	TAG	</name>
752	TOK	lymphocytes		lymphocyte\N5P
753	TOK	and		and\CC
754	TOK	plasma		plasma\N5S
755	TOK	concentrations		concentration\N5P
756	TOK	of		of\P
##	TAG	<name>
757	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
758	TOK	1		1\X
##	TAG	</num>
##	TAG	<name>
759	TOK	RNA		RNA\N46
##	TAG	</name>
760	TOK	were		be\V6F-A66
761	TOK	defined		define\VMC----
762	TOK	as		as\P
763	TOK	the		the\AT---6
764	TOK	mean		mean\JA
765	TOK	of		of\P
##	TAG	<num>
766	TOK	two		two\X
##	TAG	</num>
767	TOK	such		such\JA
768	TOK	measures		measure\N5P
769	TOK	obtained		obtain\VMC----
770	TOK	during		during\P
771	TOK	the		the\AT---6
##	TAG	<num>
772	TOK	10		10\X
##	TAG	</num>
773	TOK	days		day\N5P
774	TOK	before		before\P
775	TOK	randomisation		randomisation\N5P
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
776	TOK	After	BOS	after\P
777	TOK	randomisation		randomisation\N5P
---	DLD	,		=\DELIM
778	TOK	medical		medical\JA
779	TOK	history		history\N5S
---	DLD	,		=\DELIM
780	TOK	physical		physical\JA
781	TOK	examination		examination\N5S
---	DLD	,		=\DELIM
782	TOK	laboratory		laboratory\N5S
783	TOK	testing		testing\N5S
784	TOK	for		for\P
785	TOK	toxic		toxic\JA
786	TOK	effects		effect\N5P
787	TOK	and		and\CC
788	TOK	surrogate		surrogate\N5S
789	TOK	markers		marker\N5P
---	DLD	,		=\DELIM
790	TOK	and		and\CC
791	TOK	compliance		compliance\N5S
792	TOK	checks		check\VMFDRS3
---	DLE	(		=\DELIM
793	TOK	by		by\P
794	TOK	measurement		measurement\N5S
795	TOK	of		of\P
796	TOK	residual		residual\JA
797	TOK	amounts		amount\N5P
798	TOK	of		of\P
799	TOK	study		study\N5S
800	TOK	medication		medication\N5S
---	DLD	)		=\DELIM
801	TOK	were		be\V6F-A66
802	TOK	repeated		repeat\VMC----
803	TOK	weekly		weekly\JA
804	TOK	for		for\P
805	TOK	the		the\AT---6
806	TOK	first		first\MOS
807	TOK	month		month\N5S
---	DLD	,		=\DELIM
808	TOK	every		every\AG---S
##	TAG	<num>
809	TOK	2		2\X
##	TAG	</num>
810	TOK	weeks		week\N5P
811	TOK	for		for\P
812	TOK	the		the\AT---6
813	TOK	next		next\JA
##	TAG	<num>
814	TOK	2		2\X
##	TAG	</num>
815	TOK	months		month\N5P
---	DLD	,		=\DELIM
816	TOK	and		and\CC
817	TOK	monthly		monthly\JA
818	TOK	thereafter		thereafter\DGA7
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
819	TOK	The	BOS	the\AT---6
820	TOK	assessment		assessment\N5S
821	TOK	was		be\V6F-A66
822	TOK	repeated		repeat\VMC----
823	TOK	on		on\P
824	TOK	discontinuation		discontinuation\N5S
825	TOK	of		of\P
826	TOK	study		study\N5S
827	TOK	medication		medication\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
828	TOK	All	BOS	all\AG---6
829	TOK	haematological		haematological\JA
830	TOK	and		and\CC
831	TOK	biochemical		biochemical\JA
832	TOK	tests		test\N5P
833	TOK	were		be\V6F-A66
834	TOK	done		do\VMC----
835	TOK	in		in\P
836	TOK	central		central\JA
837	TOK	laboratories		laboratory\N5P
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<head>
838	TOK	Treatment	BOS	treatment\N5S
839	TOK	and		and\CC
840	TOK	follow		follow\VMF6R66
---	DLI	-		=\DELIM
841	TOK	up	EOS	up\N5S
##	TAG	</head>
##	TAG	<p>
##	TAG	<s>
843	TOK	There	BOS	there\DGA7
844	TOK	were		be\V6F-A66
##	TAG	<num>
845	TOK	three		three\X
##	TAG	</num>
846	TOK	study		study\N5S
847	TOK	periods		period\N5P
848	TOK	of		of\P
849	TOK	drug		drug\N5S
850	TOK	management		management\N5S
851	TOK	with		with\P
852	TOK	study		study\N5S
853	TOK	medication		medication\N5S
854	TOK	and		and\CC
855	TOK	concurrent		concurrent\JA
856	TOK	anti		anti\JA
---	DLD	-		=\DELIM
##	TAG	<name>
857	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
858	TOK	1		1\X
##	TAG	</num>
859	TOK	treatment		treatment\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
860	TOK	During	BOS	during\P
861	TOK	the		the\AT---6
862	TOK	first		first\MOS
##	TAG	<num>
863	TOK	16		16\X
##	TAG	</num>
864	TOK	weeks		week\N5P
---	DLD	,		=\DELIM
865	TOK	patients		patient\N5P
866	TOK	received		receive\VMC----
867	TOK	masked		mask\VMC----
868	TOK	study		study\N5S
869	TOK	medication		medication\N5S
870	TOK	and		and\CC
871	TOK	baseline		baseline\N5S
872	TOK	concurrent		concurrent\JA
873	TOK	anti		anti\JA
---	DLD	-		=\DELIM
##	TAG	<name>
874	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
875	TOK	1		1\X
##	TAG	</num>
876	TOK	treatment		treatment\N5S
877	TOK	that		that\RW63N6
878	TOK	could		can\VOFDA66
879	TOK	not		not\DGA7
880	TOK	be		be\VMI----
881	TOK	changed		change\VMC----
882	TOK	under		under\P
883	TOK	the		the\AT---6
884	TOK	protocol		protocol\N5S
---	DLE	(		=\DELIM
885	TOK	unless		unless\CS
886	TOK	it		it\RPS3N6
887	TOK	had		have\V6F6A66
888	TOK	to		to\P
889	TOK	be		be\VMI----
890	TOK	stopped		stop\VMC----
891	TOK	for		for\P
892	TOK	intolerance		intolerance\N5S
---	DLD	)		=\DELIM
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
893	TOK	During	BOS	during\P
894	TOK	the		the\AT---6
895	TOK	second		second\MOS
896	TOK	period		period\N5S
---	DLD	,		=\DELIM
897	TOK	from		from\P
##	TAG	<num>
898	TOK	16		16\X
##	TAG	</num>
899	TOK	weeks		week\N5P
900	TOK	after		after\P
901	TOK	randomisation		randomisation\N5S
902	TOK	until		until\P
903	TOK	provision		provision\N5S
904	TOK	of		of\P
905	TOK	open		open\VMI----
---	DLI	-		=\DELIM
906	TOK	label		label\N5S
907	TOK	ritonavir		ritonavir\N5S
908	TOK	to		to\P
909	TOK	all		all\AG---6
910	TOK	patients		patient\N5P
911	TOK	after		after\P
912	TOK	the		the\AT---6
913	TOK	primary		primary\JA
914	TOK	study		study\N5S
915	TOK	objective		objective\N5S
916	TOK	was		be\V6F-A66
917	TOK	met		meet\VMC----
---	DLD	,		=\DELIM
918	TOK	patients		patient\N5P
919	TOK	who		who\RW63N-
920	TOK	developed		develop\VMF6A66
921	TOK	a		a\AI---S
922	TOK	confirmed		confirm\VMC----
##	TAG	<name>
923	TOK	AIDS		AIDS\N46
##	TAG	</name>
---	DLE	-		=\DELIM
924	TOK	defining		define\VMG----
925	TOK	outcome		outcome\N5S
926	TOK	during		during\P
927	TOK	the		the\AT---6
928	TOK	first		first\MOS
929	TOK	or		or\CC
930	TOK	the		the\AT---6
931	TOK	second		second\MOS
932	TOK	period		period\N5S
933	TOK	were		be\V6F-A66
934	TOK	given		give\VMC----
935	TOK	ritonavir		ritonavir\N5S
936	TOK	openly		openly\DGA7
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
937	TOK	Patients	BOS	patient\N5P
938	TOK	who		who\RW63N-
939	TOK	did		do\V6FDA66
940	TOK	not		not\DGA7
941	TOK	experience		experience\VMI----
942	TOK	an		an\AI---S
##	TAG	<name>
943	TOK	AIDS		AIDS\N46
##	TAG	</name>
---	DLE	-		=\DELIM
944	TOK	defining		define\VMG----
945	TOK	outcome		outcome\N5S
946	TOK	during		during\P
947	TOK	either		either\AG---6
948	TOK	period		period\N5S
949	TOK	remained		remain\VMC----
950	TOK	on		on\P
951	TOK	masked		mask\VMC----
952	TOK	study		study\N5S
953	TOK	medication		medication\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
954	TOK	In	BOS	in\P
955	TOK	addition		addition\N5S
---	DLD	,		=\DELIM
956	TOK	during		during\P
957	TOK	the		the\AT---6
958	TOK	second		second\MOS
959	TOK	period		period\N5S
960	TOK	physicians		physician\N5P
961	TOK	could		can\VOFDA66
962	TOK	alter		alter\VMI----
963	TOK	the		the\AT---6
964	TOK	concurrent		concurrent\JA
965	TOK	regimen		regimen\N5S
966	TOK	of		of\P
967	TOK	up		up\VMI----
968	TOK	to		to\P
##	TAG	<num>
969	TOK	two		two\X
##	TAG	</num>
970	TOK	licensed		license\VMC----
971	TOK	nucleosides		nucleoside\N5P
972	TOK	including		including\P
973	TOK	lamivudine		lamivudine\N5P
---	DLD	,		=\DELIM
974	TOK	which		which\RW63N-
975	TOK	became		become\VMF6A66
976	TOK	commercially		commercially\DGA7
977	TOK	available		available\JA
978	TOK	during		during\P
979	TOK	the		the\AT---6
980	TOK	study		study\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
981	TOK	During	BOS	during\P
982	TOK	the		the\AT---6
983	TOK	third		third\MOS
984	TOK	period		period\N5S
---	DLD	,		=\DELIM
985	TOK	after		after\P
986	TOK	the		the\AT---6
987	TOK	primary		primary\JA
988	TOK	objective		objective\N5S
989	TOK	was		be\V6F-A66
990	TOK	met		meet\VMC----
---	DLD	,		=\DELIM
991	TOK	all		all\AG---6
992	TOK	patients		patient\N5P
993	TOK	were		be\V6F-A66
994	TOK	offered		offer\VMC----
995	TOK	open		open\DGA7
---	DLI	-		=\DELIM
996	TOK	label		label\N5S
997	TOK	ritonavir		ritonavir\N5S
998	TOK	irrespective		irrespective\JA
999	TOK	of		of\P
1000	TOK	disease		disease\N5S
1001	TOK	status		status\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
1002	TOK	Patients	BOS	patient\N5P
1003	TOK	who		who\RW63N-
1004	TOK	stopped		stop\VMF6A66
1005	TOK	masked		mask\VMC----
1006	TOK	study		study\N5S
1007	TOK	medication		medication\N5S
1008	TOK	continued		continue\VMC----
1009	TOK	scheduled		schedule\VMC----
1010	TOK	visits		visit\N5P
1011	TOK	throughout		throughout\P
1012	TOK	the		the\AT---6
1013	TOK	trial		trial\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<head>
1014	TOK	Adverse	BOS	adverse\JA
1015	TOK	events	EOS	event\N5P
##	TAG	</head>
##	TAG	<p>
##	TAG	<s>
1017	TOK	Adverse	BOS	adverse\JA
1018	TOK	events		event\N5P
1019	TOK	were		be\V6F-A66
1020	TOK	defined		define\VMC----
1021	TOK	as		as\P
1022	TOK	any		any\AG---6
1023	TOK	change		change\N5S
1024	TOK	in		in\P
1025	TOK	a		a\AI---S
1026	TOK	clinical		clinical\JA
1027	TOK	sign		sign\N5S
1028	TOK	or		or\CC
1029	TOK	symptom		symptom\N5S
---	DLD	,		=\DELIM
1030	TOK	or		or\CC
1031	TOK	meaningful		meaningful\JA
1032	TOK	laboratory		laboratory\N5S
---	DLI	-		=\DELIM
1033	TOK	test		test\N5S
1034	TOK	abnormality		abnormality\N5S
---	DLD	,		=\DELIM
1035	TOK	excluding		exclude\VMG----
1036	TOK	disorders		disorder\N5P
1037	TOK	associated		associate\VMC----
1038	TOK	with		with\P
##	TAG	<name>
1039	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
1040	TOK	1		1\X
##	TAG	</num>
1041	TOK	infection		infection\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
1042	TOK	All	BOS	all\AG---6
1043	TOK	adverse		adverse\JA
1044	TOK	events		event\N5P
1045	TOK	were		be\V6F-A66
1046	TOK	rated		rate\VMC----
##	TAG	<loc pos="P">
1047	TOK	according to		according_to\P
##	TAG	</loc>
1048	TOK	severity		severity\N5S
1049	TOK	and		and\CC
1050	TOK	relation		relation\N5S
1051	TOK	to		to\P
1052	TOK	study		study\N5S
1053	TOK	drug		drug\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<head>
1054	TOK	Statistical	BOS	statistical\JA
1055	TOK	analysis	EOS	analysis\N5S
##	TAG	</head>
##	TAG	<p>
##	TAG	<s>
1057	TOK	Sample	BOS	sample\JA
---	DLI	-		=\DELIM
1058	TOK	size		size\N5S
1059	TOK	calculations		calculation\N5P
1060	TOK	were		be\V6F-A66
1061	TOK	based		base\VMC----
1062	TOK	on		on\P
1063	TOK	an		an\AI---S
1064	TOK	estimate		estimate\N5S
1065	TOK	that		that\CS
1066	TOK	the		the\AT---6
1067	TOK	annual		annual\JA
1068	TOK	rate		rate\N5S
1069	TOK	of		of\P
1070	TOK	disease		disease\N5S
1071	TOK	progression		progression\N5S
1072	TOK	or		or\CC
1073	TOK	death		death\N5S
1074	TOK	would		will\VOFDA66
1075	TOK	be		be\VMI----
##	TAG	<num>
1076	TOK	40		40\X
##	TAG	</num>
---	DLD	%		=\DELIM
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
1077	TOK	We	BOS	we\RPP1NN
1078	TOK	assumed		assume\VMF6A66
1079	TOK	that		that\CS
1080	TOK	up		up\P
1081	TOK	to		to\P
##	TAG	<na type="function">
1082	TOK	10% of		noanat\W
##	TAG	</na>
1083	TOK	the		the\AT---6
1084	TOK	patients		patient\N5P
1085	TOK	would		will\VOFDA66
1086	TOK	be		be\VMI----
1087	TOK	lost		lose\VMC----
1088	TOK	to		to\P
1089	TOK	followup		followup\N5S
1090	TOK	before		before\P
1091	TOK	experiencing		experience\VMG----
1092	TOK	an		an\AI---S
##	TAG	<name>
1093	TOK	AIDS		AIDS\N46
##	TAG	</name>
---	DLE	-		=\DELIM
1094	TOK	defining		define\VMG----
1095	TOK	outcome		outcome\N5S
1096	TOK	event		event\N5S
---	DLD	,		=\DELIM
1097	TOK	and		and\CC
1098	TOK	sought		seek\VMF6A66
##	TAG	<num>
1099	TOK	80		80\X
##	TAG	</num>
---	DLD	%		=\DELIM
1100	TOK	power		power\N5S
1101	TOK	to		to\P
1102	TOK	detect		detect\VMI----
1103	TOK	a		a\AI---S
1104	TOK	reduction		reduction\N5S
1105	TOK	of		of\P
##	TAG	<na type="function">
1106	TOK	33% in		noanat\W
##	TAG	</na>
1107	TOK	the		the\AT---6
1108	TOK	hazard		hazard\N5S
1109	TOK	ratio		ratio\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
1110	TOK	With	BOS	with\P
1111	TOK	rapid		rapid\JA
1112	TOK	accrual		accrual\N5S
1113	TOK	of		of\P
1114	TOK	the		the\AT---6
1115	TOK	estimated		estimate\VMF6A66
##	TAG	<num>
1116	TOK	350		350\X
##	TAG	</num>
1117	TOK	patients		patient\N5P
1118	TOK	per		per\P
1119	TOK	treatment		treatment\N5S
1120	TOK	group		group\VMF6R66
---	DLD	,		=\DELIM
1121	TOK	the		the\AT---6
1122	TOK	final		final\JA
1123	TOK	analysis		analysis\N5S
1124	TOK	of		of\P
1125	TOK	disease		disease\N5S
1126	TOK	progression		progression\N5S
1127	TOK	or		or\CC
1128	TOK	death		death\N5S
1129	TOK	was		be\V6F-A66
1130	TOK	originally		originally\DGA7
1131	TOK	scheduled		schedule\VMC----
1132	TOK	to		to\P
1133	TOK	occur		occur\VMI----
1134	TOK	after		after\P
##	TAG	<num>
1135	TOK	191		191\X
##	TAG	</num>
1136	TOK	patients		patient\N5P
1137	TOK	experienced		experience\VMF6A66
1138	TOK	such		such\JA
1139	TOK	an		an\AI---S
1140	TOK	event		event\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
1141	TOK	However	BOS	however\DGA7
---	DLD	,		=\DELIM
1142	TOK	because		because\CS
1143	TOK	accrual		accrual\N5S
1144	TOK	was		be\V6F-A66
1145	TOK	more		more\DDC7
1146	TOK	rapid		rapid\JA
1147	TOK	than		than\CS
1148	TOK	expected		expect\VMF6A66
---	DLD	,		=\DELIM
1149	TOK	the		the\AT---6
1150	TOK	sample		sample\JA
1151	TOK	size		size\N5S
1152	TOK	was		be\V6F-A66
1153	TOK	increased		increase\VMC----
1154	TOK	to		to\P
1155	TOK	about		about\DGA7
##	TAG	<num>
1156	TOK	500		500\X
##	TAG	</num>
1157	TOK	patients		patient\N5P
1158	TOK	per		per\P
1159	TOK	treatment		treatment\N5S
1160	TOK	group		group\N5S
1161	TOK	with		with\P
1162	TOK	the		the\AT---6
1163	TOK	final		final\JA
1164	TOK	analysis		analysis\N5S
1165	TOK	of		of\P
1166	TOK	disease		disease\N5S
1167	TOK	progression		progression\N5S
1168	TOK	or		or\CC
1169	TOK	death		death\N5S
1170	TOK	occurring		occur\VMG----
1171	TOK	after		after\P
1172	TOK	the		the\AT---6
1173	TOK	same		same\JA
1174	TOK	threshold		threshold\N5S
1175	TOK	of		of\P
1176	TOK	events		event\N5P
1177	TOK	was		be\V6F-A66
1178	TOK	achieved		achieve\VMC----
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
1179	TOK	All	BOS	all\AG---6
1180	TOK	analyses		analysis\N5P
1181	TOK	were		be\V6F-A66
1182	TOK	by		by\P
1183	TOK	intention		intention\N5S
1184	TOK	to		to\P
1185	TOK	treat		treat\VMI----
---	DLD	,		=\DELIM
1186	TOK	with		with\P
1187	TOK	two		two\MCP
---	DLI	-		=\DELIM
1188	TOK	sided		side\VMC----
1189	TOK	hypothesis		hypothesis\N5S
1190	TOK	tests		test\N5P
1191	TOK	at		at\P
1192	TOK	the		the\AT---6
1193	TOK	xxx		noanat\W
1194	TOK	level		level\N5S
1195	TOK	of		of\P
1196	TOK	significance		significance\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
1197	TOK	Calculations	BOS	calculation\N5P
1198	TOK	were		be\V6F-A66
1199	TOK	done		do\VMC----
1200	TOK	with		with\P
##	TAG	<name>
1201	TOK	SAS		SAS\N46
##	TAG	</name>
1202	TOK	software		software\N5S
---	DLE	(		=\DELIM
1203	TOK	version		version\N5S
##	TAG	<num>
1204	TOK	6		6\X
##	TAG	</num>
---	DLE	,		=\DELIM
##	TAG	<num>
1205	TOK	4th		4th\X
##	TAG	</num>
1206	TOK	edition		edition\N5S
---	DLD	)		=\DELIM
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
1207	TOK	Time	BOS	time\N5S
1208	TOK	to		to\P
1209	TOK	disease		disease\N5S
1210	TOK	progression		progression\N5S
1211	TOK	or		or\CC
1212	TOK	death		death\N5S
---	DLD	,		=\DELIM
##	TAG	<loc pos="DGA7">
1213	TOK	as well as		as_well_as\DGA7
##	TAG	</loc>
1214	TOK	the		the\AT---6
1215	TOK	time		time\N5S
1216	TOK	to		to\P
1217	TOK	death		death\N5S
1218	TOK	from		from\P
1219	TOK	any		any\AG---6
1220	TOK	cause		cause\VMF6R66
---	DLD	,		=\DELIM
1221	TOK	were		be\V6F-A66
1222	TOK	analysed		analyse\VMC----
1223	TOK	with		with\P
1224	TOK	a		a\AI---S
##	TAG	<name>
1225	TOK	Cox		Cox\N46
##	TAG	</name>
1226	TOK	proportional		proportional\JA
---	DLI	-		=\DELIM
1227	TOK	hazards		hazard\N5P
1228	TOK	model		model\N5S
1229	TOK	stratified		stratify\VMC----
1230	TOK	by		by\P
1231	TOK	geographical		geographical\JA
1232	TOK	region		region\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
1233	TOK	Comparisons	BOS	comparison\N5P
1234	TOK	between		between\P
1235	TOK	randomisation		randomisation\N5S
1236	TOK	groups		group\N5P
1237	TOK	used		use\VMF6A66
1238	TOK	the		the\AT---6
1239	TOK	log		log\N5S
---	DLI	-		=\DELIM
1240	TOK	rank		rank\JA
1241	TOK	test		test\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
1242	TOK	In	BOS	in\P
1243	TOK	addition		addition\N5S
---	DLD	,		=\DELIM
1244	TOK	unstratified		unstratified\JA
##	TAG	<name>
1245	TOK	Kaplan-Meier		Kaplan-Meier\N46
##	TAG	</name>
1246	TOK	curves		curve\N5P
1247	TOK	were		be\V6F-A66
1248	TOK	used		use\VMC----
1249	TOK	to		to\P
1250	TOK	display		display\VMI----
1251	TOK	these		this\AD---P
1252	TOK	data		data\N56
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
1253	TOK	The	BOS	the\AT---6
1254	TOK	assumption		assumption\N5S
1255	TOK	of		of\P
1256	TOK	a		a\AI---S
1257	TOK	constant		constant\JA
1258	TOK	hazard		hazard\N5S
1259	TOK	ratio		ratio\N5S
1260	TOK	over		over\P
1261	TOK	time		time\N5S
1262	TOK	was		be\V6F-A66
1263	TOK	tested		test\VMC----
1264	TOK	by		by\P
1265	TOK	calculating		calculate\VMG----
1266	TOK	the		the\AT---6
1267	TOK	logarithm		logarithm\N5S
1268	TOK	of		of\P
1269	TOK	the		the\AT---6
1270	TOK	negative		negative\JA
1271	TOK	logarithm		logarithm\N5S
1272	TOK	of		of\P
1273	TOK	the		the\AT---6
##	TAG	<name>
1274	TOK	Kaplan-Meier		Kaplan-Meier\N46
##	TAG	</name>
1275	TOK	estimates		estimate\N5P
1276	TOK	for		for\P
1277	TOK	intergroup		intergroup\N5S
1278	TOK	parallelism		parallelism\N5S
1279	TOK	within		within\P
1280	TOK	geographic		geographic\JA
1281	TOK	region		region\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
1282	TOK	Patients	BOS	patient\N5P
1283	TOK	were		be\V6F-A66
1284	TOK	further		further\DGA7
1285	TOK	classified		classify\VMC----
##	TAG	<loc pos="P">
1286	TOK	according to		according_to\P
##	TAG	</loc>
1287	TOK	baseline		baseline\N5S
1288	TOK	demographic		demographic\JA
1289	TOK	data		data\N56
---	DLE	(		=\DELIM
1290	TOK	mean		mean\JA
1291	TOK	of		of\P
1292	TOK	all		all\AG---6
1293	TOK	values		value\N5P
1294	TOK	for		for\P
##	TAG	<name>
1295	TOK	CD4		CD4\N46
##	TAG	</name>
---	DLE	-		=\DELIM
1296	TOK	lymphocyte		lymphocyte\N5S
1297	TOK	count		count\N5S
1298	TOK	obtained		obtain\VMC----
1299	TOK	within		within\P
##	TAG	<num>
1300	TOK	10		10\X
##	TAG	</num>
1301	TOK	days		day\N5P
1302	TOK	before		before\P
1303	TOK	randomisation		randomisation\N5S
1304	TOK	and		and\CC
1305	TOK	number		number\N5S
1306	TOK	of		of\P
1307	TOK	nucleoside		nucleoside\N5S
1308	TOK	analogues		analogue\N5P
1309	TOK	taken		take\VMC----
1310	TOK	at		at\P
1311	TOK	baseline		baseline\N5S
---	DLD	)		=\DELIM
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
1312	TOK	We	BOS	we\RPP1NN
1313	TOK	then		then\DGA7
1314	TOK	tested		test\VMF6A66
1315	TOK	for		for\P
1316	TOK	interaction		interaction\N5S
1317	TOK	between		between\P
1318	TOK	randomisation		randomisation\N5S
1319	TOK	group		group\N5S
1320	TOK	and		and\CC
1321	TOK	baseline		baseline\N5S
1322	TOK	status		status\N5S
1323	TOK	by		by\P
1324	TOK	a		a\AI---S
1325	TOK	likelihood		likelihood\N5S
1326	TOK	ratio		ratio\N5S
1327	TOK	test		test\N5S
1328	TOK	comparing		compare\VMG----
1329	TOK	proportional		proportional\JA
---	DLI	-		=\DELIM
1330	TOK	hazards		hazard\N5P
1331	TOK	models		model\N5P
1332	TOK	with		with\P
1333	TOK	and		and\CC
1334	TOK	without		without\P
1335	TOK	the		the\AT---6
1336	TOK	interaction		interaction\N5S
1337	TOK	term		term\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
1338	TOK	Reports	BOS	report\N5P
1339	TOK	of		of\P
1340	TOK	deaths		death\N5P
1341	TOK	were		be\V6F-A66
1342	TOK	sent		send\VMC----
1343	TOK	to		to\P
1344	TOK	an		an\AI---S
1345	TOK	independent		independent\JA
1346	TOK	safety		safety\N5S
1347	TOK	monitoring		monitor\VMG----
1348	TOK	board		board\VMF6R66
---	DLE	(		=\DELIM
##	TAG	<name>
1349	TOK	RW		RW\N46
##	TAG	</name>
---	DLE	,		=\DELIM
##	TAG	<name>
1350	TOK	RP		RP\N46
##	TAG	</name>
---	DLE	,		=\DELIM
##	TAG	<name>
1351	TOK	DD		DD\N46
##	TAG	</name>
---	DLE	)		=\DELIM
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
1353	TOK	The	BOS	the\AT---6
1354	TOK	protocol		protocol\N5S
1355	TOK	specified		specify\VMC----
1356	TOK	that		that\CS
1357	TOK	the		the\AT---6
##	TAG	<name>
1358	TOK	O'Brien-Fleming		O'Brien-Fleming\N46
##	TAG	</name>
1359	TOK	stopping		stop\VMG----
1360	TOK	rule		rule\N5S
1361	TOK	should		shall\VOFDA66
1362	TOK	be		be\VMI----
1363	TOK	applied		apply\VMC----
1364	TOK	for		for\P
1365	TOK	the		the\AT---6
1366	TOK	premature		premature\JA
1367	TOK	discontinuation		discontinuation\N5S
1368	TOK	of		of\P
1369	TOK	the		the\AT---6
1370	TOK	study		study\N5S
1371	TOK	as		as\P
1372	TOK	a		a\AI---S
1373	TOK	result		result\N5S
1374	TOK	of		of\P
1375	TOK	deaths		death\N5P
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
##	TAG	<num>
1376	TOK	Two	BOS	Two\X
##	TAG	</num>
1377	TOK	interim		interim\N5S
1378	TOK	analyses		analysis\N5P
1379	TOK	were		be\V6F-A66
1380	TOK	done		do\VMC----
1381	TOK	before		before\P
1382	TOK	the		the\AT---6
1383	TOK	end		end\N5S
1384	TOK	of		of\P
1385	TOK	the		the\AT---6
1386	TOK	double		double\JA
1387	TOK	blind		blind\JA
1388	TOK	part		part\N5S
1389	TOK	of		of\P
1390	TOK	this		this\AD---S
1391	TOK	study		study\N5S
---	DLE	(		=\DELIM
1392	TOK	based		base\VMC----
1393	TOK	on		on\P
1394	TOK	results		result\N5P
1395	TOK	from		from\P
1396	TOK	the		the\AT---6
1397	TOK	analysis		analysis\N5S
1398	TOK	of		of\P
1399	TOK	time		time\N5S
1400	TOK	to		to\P
1401	TOK	disease		disease\N5S
1402	TOK	progression		progression\N5S
1403	TOK	or		or\CC
1404	TOK	death		death\N5S
---	DLD	)		=\DELIM
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<head>
1405	TOK	Results	BOS	result\N5P
tf	TOK		EOS	=\DELS
##	TAG	</head>
##	TAG	<p>
##	TAG	<s>
1407	TOK	Patients	BOS	patient\N5P
1408	TOK	were		be\V6F-A66
1409	TOK	recruited		recruit\VMC----
1410	TOK	to		to\P
1411	TOK	the		the\AT---6
1412	TOK	study		study\N5S
1413	TOK	between		between\P
##	TAG	<date pos="T" ISO8601="1995-04-">
1414	TOK	April, 1995		April,_1995\T
##	TAG	</date>
---	DLE	,		=\DELIM
1415	TOK	and		and\CC
##	TAG	<date pos="T" ISO8601="1995-07-">
1416	TOK	July, 1995		July,_1995\T
##	TAG	</date>
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
##	TAG	<num>
1417	TOK	1716	BOS	1716\X
##	TAG	</num>
1418	TOK	patients		patient\N5P
1419	TOK	were		be\V6F-A66
1420	TOK	screened		screen\VMC----
---	DLD	,		=\DELIM
1421	TOK	and		and\CC
##	TAG	<num>
1422	TOK	626		626\X
##	TAG	</num>
1423	TOK	were		be\V6F-A66
1424	TOK	excluded		exclude\VMC----
---	DLE	(		=\DELIM
1425	TOK	figure		figure\N5S
##	TAG	<num>
1426	TOK	1		1\X
##	TAG	</num>
---	DLE	)		=\DELIM
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
1427	TOK	Of	BOS	of\P
1428	TOK	the		the\AT---6
##	TAG	<num>
1429	TOK	1090		1090\X
##	TAG	</num>
1430	TOK	patients		patient\N5P
1431	TOK	randomised		randomised\JA
---	DLE	(		=\DELIM
##	TAG	<num>
1432	TOK	543		543\X
##	TAG	</num>
1433	TOK	to		to\P
1434	TOK	ritonavir		ritonavir\N5S
---	DLD	,		=\DELIM
##	TAG	<num>
1435	TOK	547		547\X
##	TAG	</num>
1436	TOK	to		to\P
1437	TOK	placebo		placebo\N5S
---	DLD	)		=\DELIM
---	DLD	,		=\DELIM
##	TAG	<num>
1438	TOK	two		two\X
##	TAG	</num>
1439	TOK	in		in\P
1440	TOK	each		each\AG---S
1441	TOK	treatment		treatment\N5S
1442	TOK	group		group\N5S
1443	TOK	did		do\V6FDA66
1444	TOK	not		not\DGA7
1445	TOK	receive		receive\VMI----
1446	TOK	any		any\AG---6
1447	TOK	trial		trial\N5S
1448	TOK	medication		medication\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
1449	TOK	These	BOS	this\AD---P
1450	TOK	patients		patient\N5P
1451	TOK	were		be\V6F-A66
1452	TOK	included		include\VMC----
1453	TOK	in		in\P
1454	TOK	the		the\AT---6
1455	TOK	primary		primary\JA
---	DLD	,		=\DELIM
1456	TOK	intention		intention\N5S
---	DLI	-		=\DELIM
1457	TOK	to		to\P
---	DLI	-		=\DELIM
1458	TOK	treat		treat\N5S
1459	TOK	analysis		analysis\N5S
---	DLD	,		=\DELIM
1460	TOK	but		but\CC
1461	TOK	they		they\RPP3NN
1462	TOK	were		be\V6F-A66
1463	TOK	excluded		exclude\VMC----
1464	TOK	from		from\P
1465	TOK	the		the\AT---6
1466	TOK	analysis		analysis\N5S
1467	TOK	of		of\P
1468	TOK	adverse		adverse\JA
1469	TOK	events		event\N5P
1470	TOK	attributable		attributable\JA
1471	TOK	to		to\P
1472	TOK	study		study\N5S
1473	TOK	drugs		drug\N5P
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
1474	TOK	Patients	BOS	patient\N5P
---	DLE	(		=\DELIM
1475	TOK	table		table\VMF6R66
##	TAG	<num>
1476	TOK	1		1\X
##	TAG	</num>
---	DLE	)		=\DELIM
1477	TOK	were		be\V6F-A66
1478	TOK	enrolled		enroll\VMC----
1479	TOK	at		at\P
##	TAG	<num>
1480	TOK	67		67\X
##	TAG	</num>
1481	TOK	centres		centre\N5P
1482	TOK	in		in\P
##	TAG	<name>
1483	TOK	Australia		Australia\N46
##	TAG	</name>
---	DLE	(		=\DELIM
##	TAG	<num>
1484	TOK	42		42\X
##	TAG	</num>
1485	TOK	patients		patient\N5P
---	DLD	)		=\DELIM
---	DLD	,		=\DELIM
##	TAG	<name>
1486	TOK	Europe		Europe\N46
##	TAG	</name>
---	DLE	(		=\DELIM
##	TAG	<num>
1487	TOK	238		238\X
##	TAG	</num>
1488	TOK	patients		patient\N5P
---	DLD	)		=\DELIM
---	DLD	,		=\DELIM
1489	TOK	and		and\CC
##	TAG	<name>
1490	TOK	North America		North_America\N46
##	TAG	</name>
---	DLE	(		=\DELIM
##	TAG	<num>
1491	TOK	810		810\X
##	TAG	</num>
1492	TOK	patients		patient\N5P
---	DLD	)		=\DELIM
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
##	TAG	<num>
1493	TOK	97	BOS	97\X
##	TAG	</num>
---	DLD	%		=\DELIM
1494	TOK	of		of\P
1495	TOK	patients		patient\N5P
1496	TOK	in		in\P
1497	TOK	the		the\AT---6
1498	TOK	ritonavir		ritonavir\N5S
1499	TOK	group		group\N5S
1500	TOK	and		and\CC
##	TAG	<na type="function">
1501	TOK	95% of		noanat\W
##	TAG	</na>
1502	TOK	those		that\RDP3N-
1503	TOK	in		in\P
1504	TOK	the		the\AT---6
##	TAG	<foreign lang="LA" pos="N5S">
1505	TOK	placebo		placebo\N5S
##	TAG	</foreign>
1506	TOK	group		group\N5S
1507	TOK	had		have\V6F6A66
1508	TOK	had		have\VMC----
##	TAG	<loc pos="DGA7">
1509	TOK	one or more		one_or_more\DGA7
##	TAG	</loc>
##	TAG	<name>
1510	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
1511	TOK	1		1\X
##	TAG	</num>
---	DLE	-		=\DELIM
1512	TOK	associated		associate\VMC----
1513	TOK	disorders		disorder\N5P
1514	TOK	before		before\P
1515	TOK	the		the\AT---6
1516	TOK	study		study\N5S
1517	TOK	began		begin\VMF6A66
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
1518	TOK	The	BOS	the\AT---6
1519	TOK	most		most\DDS7
1520	TOK	frequent		frequent\JA
##	TAG	<name>
1521	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
1522	TOK	1		1\X
##	TAG	</num>
---	DLE	-		=\DELIM
1523	TOK	related		relate\VMC----
1524	TOK	events		event\N5P
1525	TOK	reported		report\VMC----
1526	TOK	before		before\P
1527	TOK	the		the\AT---6
1528	TOK	study		study\N5S
1529	TOK	were		be\V6F-A66
1530	TOK	oral		oral\JA
1531	TOK	candidosis		candidosis\N5P
##	TAG	<num>
1532	TOK	64		64\X
##	TAG	</num>
---	DLD	%		=\DELIM
---	DLD	)		=\DELIM
---	DLD	,		=\DELIM
1533	TOK	herpes		herpes\N5S
1534	TOK	simplex		simplex\JA
---	DLE	(		=\DELIM
##	TAG	<num>
1535	TOK	28		28\X
##	TAG	</num>
---	DLD	%		=\DELIM
---	DLD	)		=\DELIM
1536	TOK	or		or\CC
1537	TOK	zoster		zoster\N5S
---	DLE	(		=\DELIM
##	TAG	<num>
1538	TOK	28		28\X
##	TAG	</num>
---	DLD	%		=\DELIM
---	DLD	)		=\DELIM
1539	TOK	infection		infection\N5S
---	DLD	,		=\DELIM
1540	TOK	hairy		hairy\JA
1541	TOK	leucoplakia		leucoplakia\N5P
---	DLE	(		=\DELIM
##	TAG	<num>
1542	TOK	27		27\X
##	TAG	</num>
---	DLD	%		=\DELIM
---	DLD	)		=\DELIM
---	DLD	,		=\DELIM
1543	TOK	peripheral		peripheral\JA
1544	TOK	neuropathy		neuropathy\N5S
---	DLE	(		=\DELIM
##	TAG	<num>
1545	TOK	26		26\X
##	TAG	</num>
---	DLD	%		=\DELIM
---	DLD	)		=\DELIM
---	DLD	,		=\DELIM
1546	TOK	persistent		persistent\JA
1547	TOK	generalised		generalised\JA
1548	TOK	lymphadenopathy		lymphadenopathy\N5S
---	DLE	(		=\DELIM
##	TAG	<num>
1549	TOK	25		25\X
##	TAG	</num>
---	DLD	%		=\DELIM
---	DLD	)		=\DELIM
---	DLD	,		=\DELIM
1550	TOK	diarrhoea		diarrhoea\N5S
---	DLE	(		=\DELIM
##	TAG	<num>
1551	TOK	20		20\X
##	TAG	</num>
---	DLD	%		=\DELIM
---	DLD	)		=\DELIM
---	DLD	,		=\DELIM
1552	TOK	and		and\CC
##	TAG	<name>
1553	TOK	Pneumocystis		Pneumocystis\N46
##	TAG	</name>
1554	TOK	carinii		carinii\N5P
1555	TOK	pneumonia		pneumonia\N5S
##	TAG	<num>
1556	TOK	25		25\X
##	TAG	</num>
---	DLD	%		=\DELIM
---	DLD	)		=\DELIM
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
1557	TOK	However	BOS	however\DGA7
---	DLD	,		=\DELIM
1558	TOK	there		there\DGA7
1559	TOK	was		be\V6F-A66
1560	TOK	no		no\AI---6
1561	TOK	apparent		apparent\JA
1562	TOK	difference		difference\N5S
1563	TOK	between		between\P
1564	TOK	the		the\AT---6
1565	TOK	randomised		randomised\JA
1566	TOK	groups		group\N5P
1567	TOK	in		in\P
1568	TOK	persistent		persistent\JA
##	TAG	<name>
1569	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
1570	TOK	1		1\X
##	TAG	</num>
---	DLE	-		=\DELIM
1571	TOK	related		relate\VMC----
1572	TOK	disorders		disorder\N5P
1573	TOK	present		present\VMF6R66
1574	TOK	at		at\P
1575	TOK	entry		entry\N5S
1576	TOK	to		to\P
1577	TOK	the		the\AT---6
1578	TOK	study		study\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
1579	TOK	Concurrent	BOS	concurrent\JA
1580	TOK	drug		drug\N5S
1581	TOK	use		use\N5S
1582	TOK	in		in\P
1583	TOK	the		the\AT---6
1584	TOK	ritonavir		ritonavir\N5S
1585	TOK	and		and\CC
##	TAG	<foreign lang="LA" pos="N5S">
1586	TOK	placebo		placebo\N5S
##	TAG	</foreign>
1587	TOK	groups		group\N5P
1588	TOK	was		be\V6F-A66
1589	TOK	similar		similar\JA
1590	TOK	before		before\P
1591	TOK	entry		entry\N5S
1592	TOK	to		to\P
1593	TOK	the		the\AT---6
1594	TOK	study		study\N5S
---	DLD	,		=\DELIM
1595	TOK	with		with\P
1596	TOK	a		a\AI---S
1597	TOK	median		median\N5S
1598	TOK	number		number\N5S
1599	TOK	of		of\P
##	TAG	<num>
1600	TOK	14		14\X
##	TAG	</num>
1601	TOK	medications		medication\N5P
1602	TOK	in		in\P
1603	TOK	each		each\AG---S
1604	TOK	group		group\N5S
---	DLE	(		=\DELIM
1605	TOK	table		table\VMF6R66
##	TAG	<num>
1606	TOK	1		1\X
##	TAG	</num>
---	DLE	)		=\DELIM
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
1607	TOK	The	BOS	the\AT---6
1608	TOK	most		most\DDS7
1609	TOK	commonly		commonly\DGA7
1610	TOK	used		use\VMC----
1611	TOK	nucleoside		nucleoside\N5S
1612	TOK	analogues		analogue\N5P
1613	TOK	at		at\P
1614	TOK	the		the\AT---6
1615	TOK	start		start\N5S
1616	TOK	of		of\P
1617	TOK	randomised		randomised\JA
1618	TOK	treatment		treatment\N5S
1619	TOK	were		be\V6F-A66
1620	TOK	zidovudine		zidovudine\N5S
---	DLE	(		=\DELIM
##	TAG	<num>
1621	TOK	45		45\X
##	TAG	</num>
---	DLD	%		=\DELIM
---	DLD	)		=\DELIM
---	DLD	,		=\DELIM
1622	TOK	stavudine		stavudine\N5S
---	DLE	(		=\DELIM
##	TAG	<num>
1623	TOK	26		26\X
##	TAG	</num>
---	DLD	%		=\DELIM
---	DLD	)		=\DELIM
---	DLD	,		=\DELIM
1624	TOK	zalcitabine		zalcitabine\N5S
---	DLE	(		=\DELIM
##	TAG	<num>
1625	TOK	19		19\X
##	TAG	</num>
---	DLD	%		=\DELIM
---	DLD	)		=\DELIM
---	DLD	,		=\DELIM
1626	TOK	and		and\CC
1627	TOK	didanosine		didanosine\N5S
##	TAG	<num>
1628	TOK	16		16\X
##	TAG	</num>
---	DLD	%		=\DELIM
---	DLD	)		=\DELIM
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
1629	TOK	The	BOS	the\AT---6
1630	TOK	median		median\N5S
1631	TOK	duration		duration\N5S
1632	TOK	of		of\P
1633	TOK	masked		mask\VMC----
1634	TOK	study		study\N5S
1635	TOK	medication		medication\N5S
1636	TOK	was		be\V6F-A66
1637	TOK	xxx		noanat\W
1638	TOK	weeks		week\N5P
1639	TOK	in		in\P
1640	TOK	patients		patient\N5P
1641	TOK	assigned		assign\VMC----
1642	TOK	ritonavir		ritonavir\N5S
1643	TOK	and		and\CC
1644	TOK	xxx		noanat\W
1645	TOK	weeks		week\N5P
1646	TOK	in		in\P
1647	TOK	patients		patient\N5P
1648	TOK	assigned		assign\VMC----
##	TAG	<foreign lang="LA" pos="N5S">
1649	TOK	placebo		placebo\N5S
##	TAG	</foreign>
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
##	TAG	<num>
1650	TOK	15	BOS	15\X
##	TAG	</num>
---	DLE	(		=\DELIM
1651	TOK	xxx		noanat\W
---	DLE	)		=\DELIM
1652	TOK	patients		patient\N5P
1653	TOK	were		be\V6F-A66
1654	TOK	lost		lose\VMC----
1655	TOK	to		to\P
1656	TOK	follow		follow\VMI----
---	DLI	-		=\DELIM
1657	TOK	up		up\N5S
1658	TOK	before		before\P
1659	TOK	period		period\N5S
##	TAG	<num>
1660	TOK	3		3\X
##	TAG	</num>
---	DLE	(		=\DELIM
1661	TOK	figure		figure\N5S
##	TAG	<num>
1662	TOK	1		1\X
##	TAG	</num>
---	DLE	,		=\DELIM
1663	TOK	including		including\P
1664	TOK	those		that\RDP3N-
1665	TOK	who		who\RW63N-
1666	TOK	received		receive\VMF6A66
1667	TOK	no		no\AI---6
1668	TOK	study		study\N5S
1669	TOK	medication		medication\N5S
---	DLD	)		=\DELIM
---	DLD	,		=\DELIM
1670	TOK	resulting		result\VMG----
1671	TOK	in		in\P
1672	TOK	a		a\AI---S
1673	TOK	median		median\N5S
1674	TOK	follow		follow\VMF6R66
---	DLI	-		=\DELIM
1675	TOK	up		up\N5S
1676	TOK	of		of\P
1677	TOK	xxx		noanat\W
1678	TOK	weeks		week\N5P
---	DLE	(		=\DELIM
1679	TOK	xxx		noanat\W
---	DLE	)		=\DELIM
1680	TOK	up		up\N5S
1681	TOK	to		to\P
1682	TOK	the		the\AT---6
1683	TOK	end		end\N5S
1684	TOK	of		of\P
1685	TOK	period		period\N5S
##	TAG	<num>
1686	TOK	2		2\X
##	TAG	</num>
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
1687	TOK	During	BOS	during\P
1688	TOK	period		period\N5S
##	TAG	<num>
1689	TOK	3		3\X
##	TAG	</num>
---	DLE	,		=\DELIM
1690	TOK	patients		patient\N5P
1691	TOK	were		be\V6F-A66
1692	TOK	offered		offer\VMC----
1693	TOK	open		open\DGA7
---	DLI	-		=\DELIM
1694	TOK	label		label\N5S
1695	TOK	ritonavir		ritonavir\N5S
1696	TOK	and		and\CC
1697	TOK	followed		follow\VMC----
1698	TOK	up		up\P
1699	TOK	for		for\P
1700	TOK	a		a\AI---S
1701	TOK	median		median\N5S
1702	TOK	total		total\JA
1703	TOK	of		of\P
1704	TOK	xxx		noanat\W
1705	TOK	weeks		week\N5P
---	DLE	(		=\DELIM
1706	TOK	xxx		noanat\W
---	DLE	)		=\DELIM
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
##	TAG	<num>
1708	TOK	76	BOS	76\X
##	TAG	</num>
---	DLE	(		=\DELIM
1709	TOK	xxx		noanat\W
---	DLE	)		=\DELIM
1710	TOK	patients		patient\N5P
1711	TOK	had		have\V6F6A66
1712	TOK	been		be\VMC----
1713	TOK	lost		lose\VMC----
1714	TOK	to		to\P
1715	TOK	follow		follow\VMI----
---	DLI	-		=\DELIM
1716	TOK	up		up\N5S
1717	TOK	by		by\P
1718	TOK	the		the\AT---6
1719	TOK	end		end\N5S
1720	TOK	of		of\P
1721	TOK	period		period\N5S
##	TAG	<num>
1722	TOK	3		3\X
##	TAG	</num>
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
##	TAG	<num>
1723	TOK	119	BOS	119\X
##	TAG	</num>
---	DLE	(		=\DELIM
1724	TOK	xxx		noanat\W
---	DLE	)		=\DELIM
1725	TOK	ritonavir		ritonavir\N5S
---	DLI	-		=\DELIM
1726	TOK	group		group\N5S
1727	TOK	patients		patient\N5P
1728	TOK	and		and\CC
##	TAG	<num>
1729	TOK	205		205\X
##	TAG	</num>
---	DLE	(		=\DELIM
1730	TOK	xxx		noanat\W
---	DLE	)		=\DELIM
1731	TOK	placebo		placebo\N5S
---	DLI	-		=\DELIM
1732	TOK	group		group\N5S
1733	TOK	patients		patient\N5P
1734	TOK	experienced		experience\VMF6A66
1735	TOK	an		an\AI---S
##	TAG	<name>
1736	TOK	AIDS		AIDS\N46
##	TAG	</name>
1737	TOK	defining		define\VMG----
1738	TOK	event		event\N5S
1739	TOK	or		or\CC
1740	TOK	death		death\N5S
1741	TOK	during		during\P
1742	TOK	periods		period\N5P
##	TAG	<num>
1743	TOK	1		1\X
##	TAG	</num>
1744	TOK	and		and\CC
##	TAG	<num>
1745	TOK	2		2\X
##	TAG	</num>
1746	TOK	of		of\P
1747	TOK	this		this\AD---S
1748	TOK	study		study\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
1749	TOK	The	BOS	the\AT---6
1750	TOK	hazard		hazard\N5S
1751	TOK	ratio		ratio\N5S
1752	TOK	was		be\V6F-A66
1753	TOK	xxx		noanat\W
---	DLE	(		=\DELIM
##	TAG	<na type="function">
1754	TOK	95% CI		noanat\W
##	TAG	</na>
1755	TOK	xxx		noanat\W
##	TAG	<na type="function">
1756	TOK	42-66		noanat\W
##	TAG	</na>
---	DLD	;		=\DELIM
1757	TOK	log		log\VMF6R66
---	DLI	-		=\DELIM
1758	TOK	rank		rank\N5S
1759	TOK	xxx		noanat\W
1760	TOK	figure		figure\N5S
##	TAG	<num>
1761	TOK	2		2\X
##	TAG	</num>
---	DLE	)		=\DELIM
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
1763	TOK	The	BOS	the\AT---6
1764	TOK	most		most\DDS7
1765	TOK	common		common\JA
1766	TOK	primary		primary\JA
1767	TOK	outcome		outcome\N5S
1768	TOK	event		event\N5S
1769	TOK	was		be\V6F-A66
1770	TOK	death		death\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
1771	TOK	The	BOS	the\AT---6
1772	TOK	most		most\DDS7
1773	TOK	common		common\JA
1774	TOK	first		first\MOS
1775	TOK	disease		disease\N5S
1776	TOK	event		event\N5S
1777	TOK	was		be\V6F-A66
1778	TOK	new		new\JA
1779	TOK	or		or\CC
1780	TOK	recurrent		recurrent\JA
1781	TOK	oesophageal		oesophageal\JA
1782	TOK	candidosis		candidosis\N5P
---	DLE	(		=\DELIM
1783	TOK	table		table\VMF6R66
##	TAG	<num>
1784	TOK	2		2\X
##	TAG	</num>
---	DLE	)		=\DELIM
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
1786	TOK	The	BOS	the\AT---6
1787	TOK	rates		rate\N5P
1788	TOK	of		of\P
1789	TOK	first		first\MOS
1790	TOK	events		event\N5P
1791	TOK	were		be\V6F-A66
1792	TOK	generally		generally\DGA7
1793	TOK	lower		low\JC
1794	TOK	in		in\P
1795	TOK	the		the\AT---6
1796	TOK	ritonavir		ritonavir\N5S
1797	TOK	group		group\N5S
1798	TOK	than		than\CS
1799	TOK	in		in\P
1800	TOK	the		the\AT---6
##	TAG	<foreign lang="LA" pos="N5S">
1801	TOK	placebo		placebo\N5S
##	TAG	</foreign>
1802	TOK	group		group\VMF6R66
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
1803	TOK	A	BOS	a\AI---S
1804	TOK	secondary		secondary\JA
1805	TOK	analysis		analysis\N5S
1806	TOK	of		of\P
1807	TOK	deaths		death\N5P
1808	TOK	during		during\P
1809	TOK	periods		period\N5P
##	TAG	<num>
1810	TOK	1		1\X
##	TAG	</num>
1811	TOK	and		and\CC
##	TAG	<num>
1812	TOK	2		2\X
##	TAG	</num>
1813	TOK	gave		give\VMF6A66
1814	TOK	an		an\AI---S
1815	TOK	estimated		estimate\VMC----
1816	TOK	hazard		hazard\N5S
1817	TOK	ratio		ratio\N5S
1818	TOK	of		of\P
1819	TOK	xxx		noanat\W
---	DLE	(		=\DELIM
##	TAG	<na type="function">
1820	TOK	95% CI		noanat\W
##	TAG	</na>
1821	TOK	xxx		noanat\W
1822	TOK	log		log\VMF6R66
---	DLI	-		=\DELIM
1823	TOK	rank		rank\N5S
1824	TOK	xxx		noanat\W
---	DLE	)		=\DELIM
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
1826	TOK	Disease	BOS	disease\N5S
1827	TOK	progression		progression\N5S
1828	TOK	or		or\CC
1829	TOK	death		death\N5S
1830	TOK	was		be\V6F-A66
1831	TOK	also		also\DGA7
1832	TOK	analysed		analyse\VMC----
1833	TOK	with		with\P
1834	TOK	either		either\AG---6
1835	TOK	baseline		baseline\N5S
##	TAG	<name>
1836	TOK	CD4		CD4\N46
##	TAG	</name>
---	DLE	-		=\DELIM
1837	TOK	lymphocyte		lymphocyte\N5S
1838	TOK	count		count\N5S
1839	TOK	or		or\CC
1840	TOK	the		the\AT---6
1841	TOK	number		number\N5S
1842	TOK	of		of\P
1843	TOK	baseline		baseline\N5S
1844	TOK	nucleoside		nucleoside\N5S
1845	TOK	analogues		analogue\N5P
1846	TOK	used		use\VMC----
1847	TOK	as		as\P
1848	TOK	stratification		stratification\N5S
1849	TOK	factors		factor\N5P
---	DLE	(		=\DELIM
1850	TOK	table		table\VMF6R66
##	TAG	<num>
1851	TOK	3		3\X
##	TAG	</num>
---	DLE	)		=\DELIM
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
1853	TOK	No	BOS	no\AI---6
1854	TOK	significant		significant\JA
1855	TOK	interaction		interaction\N5S
1856	TOK	between		between\P
1857	TOK	randomisation		randomisation\N5S
1858	TOK	group		group\N5S
1859	TOK	and		and\CC
1860	TOK	baseline		baseline\N5S
1861	TOK	factor		factor\N5S
1862	TOK	status		status\N5S
1863	TOK	was		be\V6F-A66
1864	TOK	detected		detect\VMC----
1865	TOK	in		in\P
1866	TOK	either		either\AG---6
1867	TOK	analysis		analysis\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
1868	TOK	Ritonavir	BOS	ritonavir\N5S
1869	TOK	significantly		significantly\DGA7
1870	TOK	reduced		reduce\VMF6A66
1871	TOK	the		the\AT---6
1872	TOK	risk		risk\N5S
1873	TOK	of		of\P
1874	TOK	disease		disease\N5S
1875	TOK	progression		progression\N5S
1876	TOK	or		or\CC
1877	TOK	death		death\N5S
1878	TOK	in		in\P
1879	TOK	all		all\AG---6
1880	TOK	categories		category\N5P
1881	TOK	of		of\P
1882	TOK	baseline		baseline\N5S
##	TAG	<name>
1883	TOK	CD4		CD4\N46
##	TAG	</name>
---	DLE	-		=\DELIM
1884	TOK	lymphocyte		lymphocyte\N5S
1885	TOK	count		count\N5S
1886	TOK	used		use\VMC----
1887	TOK	in		in\P
1888	TOK	this		this\AD---S
1889	TOK	analysis		analysis\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
1890	TOK	Furthermore	BOS	furthermore\DGA7
---	DLD	,		=\DELIM
1891	TOK	the		the\AT---6
1892	TOK	results		result\N5P
1893	TOK	suggest		suggest\VMF6R66
1894	TOK	that		that\CS
1895	TOK	the		the\AT---6
1896	TOK	risk		risk\N5S
1897	TOK	of		of\P
1898	TOK	disease		disease\N5S
1899	TOK	progression		progression\N5S
1900	TOK	or		or\CC
1901	TOK	death		death\N5S
1902	TOK	increased		increase\VMC----
1903	TOK	with		with\P
1904	TOK	decreasing		decrease\VMG----
1905	TOK	baseline		baseline\N5S
##	TAG	<name>
1906	TOK	CD4		CD4\N46
##	TAG	</name>
---	DLE	-		=\DELIM
1907	TOK	lymphocyte		lymphocyte\N5S
1908	TOK	count		count\VMF6R66
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
1909	TOK	Ritonavir	BOS	ritonavir\N5S
1910	TOK	alone		alone\DGA7
1911	TOK	did		do\V6FDA66
1912	TOK	not		not\DGA7
1913	TOK	significantly		significantly\DGA7
1914	TOK	reduce		reduce\VMI----
1915	TOK	the		the\AT---6
1916	TOK	risk		risk\N5S
1917	TOK	of		of\P
1918	TOK	disease		disease\N5S
1919	TOK	progression		progression\N5S
1920	TOK	or		or\CC
1921	TOK	death		death\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
1922	TOK	However	BOS	however\DGA7
---	DLD	,		=\DELIM
1923	TOK	a		a\AI---S
1924	TOK	significant		significant\JA
1925	TOK	reduction		reduction\N5S
1926	TOK	in		in\P
1927	TOK	the		the\AT---6
1928	TOK	risk		risk\N5S
1929	TOK	of		of\P
1930	TOK	disease		disease\N5S
1931	TOK	progression		progression\N5S
1932	TOK	or		or\CC
1933	TOK	death		death\N5S
1934	TOK	was		be\V6F-A66
1935	TOK	found		find\VMC----
1936	TOK	for		for\P
1937	TOK	ritonavir		ritonavir\N5S
1938	TOK	used		use\VMC----
1939	TOK	in		in\P
1940	TOK	combination		combination\N5S
1941	TOK	with		with\P
##	TAG	<loc pos="DGA7">
1942	TOK	at least		at_least\DGA7
##	TAG	</loc>
1943	TOK	one		one\MCS
1944	TOK	baseline		baseline\N5S
1945	TOK	nucleoside		nucleoside\N5S
1946	TOK	analogue		analogue\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
1947	TOK	After	BOS	after\P
1948	TOK	the		the\AT---6
1949	TOK	clinical		clinical\JA
1950	TOK	benefit		benefit\N5S
1951	TOK	of		of\P
1952	TOK	ritonavir		ritonavir\N5S
1953	TOK	had		have\V6F6A66
1954	TOK	been		be\VMC----
1955	TOK	demonstrated		demonstrate\VMF6A66
---	DLD	,		=\DELIM
1956	TOK	events		event\N5P
1957	TOK	were		be\V6F-A66
##	TAG	<loc pos="DGA7">
1958	TOK	no longer		no_longer\DGA7
##	TAG	</loc>
1959	TOK	assessed		assess\VMC----
1960	TOK	by		by\P
1961	TOK	independent		independent\JA
1962	TOK	reviewers		reviewer\N5P
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
1963	TOK	Therefore	BOS	therefore\DGA7
---	DLD	,		=\DELIM
1964	TOK	we		we\RPP1NN
1965	TOK	could		can\VOFDA66
1966	TOK	not		not\DGA7
1967	TOK	include		include\VMI----
1968	TOK	disease		disease\N5S
1969	TOK	progression		progression\N5S
1970	TOK	in		in\P
1971	TOK	an		an\AI---S
1972	TOK	analysis		analysis\N5S
1973	TOK	to		to\P
1974	TOK	the		the\AT---6
1975	TOK	end		end\N5S
1976	TOK	of		of\P
1977	TOK	period		period\N5S
##	TAG	<num>
1978	TOK	3		3\X
##	TAG	</num>
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
1979	TOK	However	BOS	however\DGA7
---	DLD	,		=\DELIM
1980	TOK	analysis		analysis\N5S
1981	TOK	of		of\P
1982	TOK	the		the\AT---6
1983	TOK	survival		survival\N5S
1984	TOK	status		status\N5S
1985	TOK	of		of\P
1986	TOK	patients		patient\N5P
1987	TOK	at		at\P
1988	TOK	the		the\AT---6
1989	TOK	end		end\N5S
1990	TOK	of		of\P
1991	TOK	period		period\N5S
##	TAG	<num>
1992	TOK	3		3\X
##	TAG	</num>
1993	TOK	was		be\V6F-A66
1994	TOK	possible		possible\JA
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
##	TAG	<num>
1995	TOK	87	BOS	87\X
##	TAG	</num>
---	DLE	(		=\DELIM
##	TAG	<num>
1996	TOK	16		16\X
##	TAG	</num>
---	DLD	%		=\DELIM
---	DLD	)		=\DELIM
1997	TOK	patients		patient\N5P
1998	TOK	assigned		assign\VMC----
1999	TOK	ritonavir		ritonavir\N5S
2000	TOK	and		and\CC
##	TAG	<num>
2001	TOK	126		126\X
##	TAG	</num>
---	DLE	(		=\DELIM
##	TAG	<num>
2002	TOK	23		23\X
##	TAG	</num>
---	DLD	%		=\DELIM
---	DLD	)		=\DELIM
2003	TOK	patients		patient\N5P
2004	TOK	assigned		assign\VMC----
##	TAG	<foreign lang="LA" pos="N5S">
2005	TOK	placebo		placebo\N5S
##	TAG	</foreign>
2006	TOK	died		die\VMF6A66
2007	TOK	from		from\P
2008	TOK	any		any\AG---6
2009	TOK	cause		cause\VMF6R66
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
2010	TOK	The	BOS	the\AT---6
2011	TOK	hazard		hazard\N5S
2012	TOK	ratio		ratio\N5S
2013	TOK	was		be\V6F-A66
2014	TOK	xxx		noanat\W
---	DLE	(		=\DELIM
##	TAG	<na type="function">
2015	TOK	95% CI		noanat\W
##	TAG	</na>
2016	TOK	xxx		noanat\W
---	DLD	;		=\DELIM
2017	TOK	log		log\VMF6R66
---	DLI	-		=\DELIM
2018	TOK	rank		rank\N5S
2019	TOK	xxx		noanat\W
---	DLD	;		=\DELIM
2020	TOK	figure		figure\N5S
##	TAG	<num>
2021	TOK	3		3\X
##	TAG	</num>
---	DLE	)		=\DELIM
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
2023	TOK	In	BOS	in\P
2024	TOK	the		the\AT---6
2025	TOK	ritonavir		ritonavir\N5S
2026	TOK	group		group\VMF6R66
---	DLE	(		=\DELIM
2027	TOK	for		for\P
2028	TOK	patients		patient\N5P
2029	TOK	who		who\RW63N-
2030	TOK	had		have\V6F6A66
2031	TOK	data		data\N56
2032	TOK	available		available\JA
2033	TOK	for		for\P
2034	TOK	all		all\AG---6
2035	TOK	time		time\N5S
2036	TOK	points		point\VMFDRS3
---	DLD	)		=\DELIM
---	DLD	,		=\DELIM
##	TAG	<name>
2037	TOK	CD4		CD4\N46
##	TAG	</name>
---	DLE	-		=\DELIM
2038	TOK	lymphocyte		lymphocyte\N5S
2039	TOK	counts		count\N5P
2040	TOK	increased		increase\VMC----
2041	TOK	from		from\P
2042	TOK	a		a\AI---S
2043	TOK	baseline		baseline\N5S
2044	TOK	mean		mean\VMF6R66
2045	TOK	of		of\P
##	TAG	<num>
2046	TOK	31		31\X
##	TAG	</num>
---	DLE	/		=\DELIM
2047	TOK	xxx		noanat\W
---	DLE	(		=\DELIM
2048	TOK	peak		peak\N5S
2049	TOK	increase		increase\VMF6R66
##	TAG	<num>
2050	TOK	57		57\X
##	TAG	</num>
---	DLE	/		=\DELIM
2051	TOK	xxx		noanat\W
---	DLE	)		=\DELIM
---	DLD	,		=\DELIM
2052	TOK	and		and\CC
##	TAG	<name>
2053	TOK	CD8		CD8\N46
##	TAG	</name>
---	DLE	-		=\DELIM
2054	TOK	lymphocyte		lymphocyte\N5S
2055	TOK	counts		count\N5P
2056	TOK	increased		increase\VMC----
2057	TOK	from		from\P
2058	TOK	a		a\AI---S
2059	TOK	baseline		baseline\N5S
2060	TOK	mean		mean\VMF6R66
2061	TOK	of		of\P
##	TAG	<num>
2062	TOK	495		495\X
##	TAG	</num>
---	DLE	/		=\DELIM
2063	TOK	xxx		noanat\W
---	DLE	(		=\DELIM
2064	TOK	peak		peak\N5S
2065	TOK	increase		increase\VMF6R66
##	TAG	<num>
2066	TOK	425		425\X
##	TAG	</num>
---	DLE	/		=\DELIM
2067	TOK	xxx		noanat\W
---	DLD	;		=\DELIM
2068	TOK	figure		figure\N5S
##	TAG	<num>
2069	TOK	4		4\X
##	TAG	</num>
---	DLE	)		=\DELIM
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
2070	TOK	The	BOS	the\AT---6
2071	TOK	higher		high\JC
##	TAG	<name>
2072	TOK	CD4		CD4\N46
##	TAG	</name>
2073	TOK	counts		count\N5P
2074	TOK	were		be\V6F-A66
2075	TOK	sustained		sustain\VMC----
2076	TOK	for		for\P
2077	TOK	ritonavir		ritonavir\N5S
2078	TOK	treated		treat\VMC----
2079	TOK	patients		patient\N5P
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
2080	TOK	The	BOS	the\AT---6
##	TAG	<name>
2081	TOK	CD8		CD8\N46
##	TAG	</name>
2082	TOK	counts		count\N5P
2083	TOK	fell		fall\VMF6A66
2084	TOK	from		from\P
2085	TOK	the		the\AT---6
2086	TOK	peak		peak\N5S
2087	TOK	in		in\P
2088	TOK	period		period\N5S
##	TAG	<num>
2089	TOK	1		1\X
##	TAG	</num>
2090	TOK	but		but\CC
2091	TOK	stabilised		stabilise\VMC----
2092	TOK	in		in\P
2093	TOK	periods		period\N5P
##	TAG	<num>
2094	TOK	2		2\X
##	TAG	</num>
2095	TOK	and		and\CC
##	TAG	<num>
2096	TOK	3		3\X
##	TAG	</num>
---	DLE	,		=\DELIM
2097	TOK	during		during\P
2098	TOK	which		which\RW63N-
2099	TOK	the		the\AT---6
2100	TOK	mean		mean\JA
2101	TOK	effects		effect\N5P
2102	TOK	for		for\P
2103	TOK	both		both\RIP3N-
##	TAG	<name>
2104	TOK	CD4		CD4\N46
##	TAG	</name>
2105	TOK	and		and\CC
##	TAG	<name>
2106	TOK	CD8		CD8\N46
##	TAG	</name>
2107	TOK	lymphocytes		lymphocyte\N5P
2108	TOK	were		be\V6F-A66
2109	TOK	matched		match\VMC----
2110	TOK	in		in\P
2111	TOK	the		the\AT---6
##	TAG	<foreign lang="LA" pos="N5S">
2112	TOK	placebo		placebo\N5S
##	TAG	</foreign>
2113	TOK	group		group\VMF6R66
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
2114	TOK	In	BOS	in\P
2115	TOK	the		the\AT---6
2116	TOK	antiviral		antiviral\JA
2117	TOK	activity		activity\N5S
2118	TOK	subset		subset\N5S
---	DLD	,		=\DELIM
2119	TOK	plasma		plasma\N5S
2120	TOK	viral		viral\JA
2121	TOK	load		load\N5S
2122	TOK	fell		fall\VMF6A66
2123	TOK	rapidly		rapidly\DGA7
2124	TOK	in		in\P
2125	TOK	patients		patient\N5P
2126	TOK	assigned		assign\VMC----
2127	TOK	ritonavir		ritonavir\N5S
---	DLD	,		=\DELIM
2128	TOK	with		with\P
2129	TOK	a		a\AI---S
2130	TOK	maximum		maximum\N5S
2131	TOK	mean		mean\JA
2132	TOK	reduction		reduction\N5S
2133	TOK	from		from\P
2134	TOK	baseline		baseline\N5S
2135	TOK	of		of\P
2136	TOK	xxx		noanat\W
2137	TOK	copies/mL		copies/mL\N5S
2138	TOK	at		at\P
##	TAG	<num>
2139	TOK	2		2\X
##	TAG	</num>
2140	TOK	weeks		week\N5P
---	DLD	,		=\DELIM
2141	TOK	followed		follow\VMC----
2142	TOK	by		by\P
2143	TOK	a		a\AI---S
2144	TOK	subsequent		subsequent\JA
2145	TOK	return		return\N5S
2146	TOK	toward		toward\P
2147	TOK	baseline		baseline\N5S
---	DLE	(		=\DELIM
2148	TOK	figure		figure\N5S
##	TAG	<num>
2149	TOK	4		4\X
##	TAG	</num>
---	DLE	)		=\DELIM
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
##	TAG	<name>
2150	TOK	HIV	BOS	HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
2151	TOK	1		1\X
##	TAG	</num>
##	TAG	<name>
2152	TOK	RNA		RNA\N46
##	TAG	</name>
2153	TOK	concentrations		concentration\N5P
2154	TOK	then		then\DGA7
2155	TOK	stabilised		stabilise\VMC----
2156	TOK	during		during\P
2157	TOK	period		period\N5S
##	TAG	<num>
2158	TOK	two		two\X
##	TAG	</num>
2159	TOK	at		at\P
2160	TOK	a		a\AI---S
2161	TOK	value		value\N5S
2162	TOK	of		of\P
2163	TOK	about		about\DGA7
2164	TOK	xxx		noanat\W
2165	TOK	copies/mL		copies/mL\N5S
2166	TOK	lower		low\JC
2167	TOK	than		than\CS
2168	TOK	baseline		baseline\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
2169	TOK	During	BOS	during\P
2170	TOK	periods		period\N5P
##	TAG	<num>
2171	TOK	2		2\X
##	TAG	</num>
2172	TOK	and		and\CC
##	TAG	<num>
2173	TOK	3		3\X
##	TAG	</num>
---	DLE	,		=\DELIM
2174	TOK	when		when\CS
2175	TOK	patients		patient\N5P
2176	TOK	switched		switch\VMC----
2177	TOK	to		to\P
2178	TOK	open		open\VMI----
---	DLI	-		=\DELIM
2179	TOK	label		label\N5S
2180	TOK	ritonavir		ritonavir\N5S
---	DLD	,		=\DELIM
2181	TOK	plasma		plasma\N5S
2182	TOK	viraemia		viraemia\N5S
2183	TOK	in		in\P
2184	TOK	the		the\AT---6
2185	TOK	remaining		remain\VMG----
2186	TOK	placebo		placebo\N5S
---	DLI	-		=\DELIM
2187	TOK	group		group\N5S
2188	TOK	patients		patient\N5P
2189	TOK	fell		fall\VMF6A66
2190	TOK	to		to\P
2191	TOK	values		value\N5P
2192	TOK	below		below\P
2193	TOK	those		that\RDP3N-
2194	TOK	observed		observe\VMC----
2195	TOK	in		in\P
2196	TOK	the		the\AT---6
2197	TOK	remaining		remain\VMG----
2198	TOK	ritonavir		ritonavir\N5S
2199	TOK	group		group\N5S
2200	TOK	patients		patient\N5P
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<head>
2201	TOK	Adverse	BOS	adverse\JA
2202	TOK	effects	EOS	effect\N5P
##	TAG	</head>
##	TAG	<p>
##	TAG	<s>
2204	TOK	Overall	BOS	overall\JA
##	TAG	<num>
2205	TOK	114		114\X
##	TAG	</num>
---	DLE	(		=\DELIM
2206	TOK	xxx		noanat\W
---	DLE	)		=\DELIM
2207	TOK	of		of\P
2208	TOK	patients		patient\N5P
2209	TOK	in		in\P
2210	TOK	the		the\AT---6
2211	TOK	ritonavir		ritonavir\N5S
2212	TOK	group		group\N5S
2213	TOK	and		and\CC
##	TAG	<num>
2214	TOK	45		45\X
##	TAG	</num>
---	DLE	(		=\DELIM
2215	TOK	xxx		noanat\W
---	DLE	)		=\DELIM
2216	TOK	of		of\P
2217	TOK	patients		patient\N5P
2218	TOK	in		in\P
2219	TOK	the		the\AT---6
##	TAG	<foreign lang="LA" pos="N5S">
2220	TOK	placebo		placebo\N5S
##	TAG	</foreign>
2221	TOK	group		group\N5S
2222	TOK	withdrew		withdraw\VMF6A66
2223	TOK	from		from\P
2224	TOK	treatment		treatment\N5S
2225	TOK	with		with\P
2226	TOK	masked		mask\VMC----
2227	TOK	study		study\N5S
2228	TOK	medication		medication\N5S
---	DLE	(		=\DELIM
2229	TOK	xxx		noanat\W
---	DLE	)		=\DELIM
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
2231	TOK	However	BOS	however\DGA7
---	DLD	,		=\DELIM
2232	TOK	many		many\AI---P
2233	TOK	of		of\P
2234	TOK	those		that\RDP3N-
2235	TOK	in		in\P
2236	TOK	the		the\AT---6
2237	TOK	ritonavir		ritonavir\N5S
2238	TOK	group		group\N5S
2239	TOK	withdrew		withdraw\VMF6A66
2240	TOK	from		from\P
2241	TOK	treatment		treatment\N5S
2242	TOK	during		during\P
2243	TOK	the		the\AT---6
2244	TOK	first		first\MOS
##	TAG	<num>
2245	TOK	4		4\X
##	TAG	</num>
2246	TOK	weeks		week\N5P
2247	TOK	of		of\P
2248	TOK	treatment		treatment\N5S
---	DLD	;		=\DELIM
##	TAG	<na type="function">
2249	TOK	9% of		noanat\W
##	TAG	</na>
2250	TOK	the		the\AT---6
2251	TOK	ritonavir		ritonavir\N5S
2252	TOK	group		group\N5S
2253	TOK	and		and\CC
##	TAG	<na type="function">
2254	TOK	1% of		noanat\W
##	TAG	</na>
2255	TOK	the		the\AT---6
##	TAG	<foreign lang="LA" pos="N5S">
2256	TOK	placebo		placebo\N5S
##	TAG	</foreign>
2257	TOK	group		group\N5S
2258	TOK	withdrew		withdraw\VMF6A66
2259	TOK	from		from\P
2260	TOK	masked		mask\VMC----
2261	TOK	study		study\N5S
2262	TOK	medication		medication\N5S
2263	TOK	during		during\P
2264	TOK	period		period\N5S
##	TAG	<num>
2265	TOK	1		1\X
##	TAG	</num>
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
2266	TOK	Table	BOS	table\VMF6R66
##	TAG	<num>
2267	TOK	4		4\X
##	TAG	</num>
2268	TOK	lists		list\VMFDRS3
2269	TOK	the		the\AT---6
2270	TOK	most		most\DDS7
2271	TOK	frequently		frequently\DGA7
2272	TOK	reported		report\VMF6A66
2273	TOK	adverse		adverse\JA
2274	TOK	events		event\N5P
2275	TOK	and		and\CC
2276	TOK	reasons		reason\N5P
2277	TOK	for		for\P
2278	TOK	withdrawal		withdrawal\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
2279	TOK	These	BOS	this\AD---P
2280	TOK	events		event\N5P
2281	TOK	were		be\V6F-A66
2282	TOK	most		most\DDS7
2283	TOK	commonly		commonly\DGA7
2284	TOK	classified		classify\VMC----
2285	TOK	as		as\P
2286	TOK	gastrointestinal		gastrointestinal\JA
2287	TOK	symptoms		symptom\N5P
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
2288	TOK	Abnormal	BOS	abnormal\JA
2289	TOK	results		result\N5P
2290	TOK	of		of\P
2291	TOK	biochemical		biochemical\JA
2292	TOK	laboratory		laboratory\N5S
2293	TOK	tests		test\N5P
2294	TOK	were		be\V6F-A66
2295	TOK	more		more\DDC7
2296	TOK	common		common\JA
2297	TOK	with		with\P
2298	TOK	ritonavir		ritonavir\N5S
2299	TOK	than		than\CS
2300	TOK	with		with\P
2301	TOK	placebo		placebo\N5S
---	DLD	:		=\DELIM
2302	TOK	high		high\JA
2303	TOK	concentrations		concentration\N5P
2304	TOK	of		of\P
2305	TOK	alanine		alanine\N5S
2306	TOK	aminotransferase		aminotransferase\N5S
---	DLE	(		=\DELIM
##	TAG	<num>
2307	TOK	>215		>215\X
##	TAG	</num>
##	TAG	<na type="function">
2308	TOK	IU/L		noanat\W
##	TAG	</na>
---	DLE	)		=\DELIM
2309	TOK	occurred		occur\VMC----
2310	TOK	in		in\P
2311	TOK	xxx		noanat\W
##	TAG	<foreign lang="LA" pos="P">
2312	TOK	versus		versus\P
##	TAG	</foreign>
2313	TOK	xxx		noanat\W
2314	TOK	g-glutamyl		g-glutamyl\N5S
2315	TOK	transpeptidase		transpeptidase\N5S
2316	TOK	above		above\P
##	TAG	<num>
2317	TOK	300		300\X
##	TAG	</num>
2318	TOK	xxx		noanat\W
2319	TOK	in		in\P
2320	TOK	xxx		noanat\W
##	TAG	<foreign lang="LA" pos="P">
2321	TOK	versus		versus\P
##	TAG	</foreign>
2322	TOK	xxx		noanat\W
2323	TOK	creatine		creatine\N5S
2324	TOK	phosphokinase		phosphokinase\N5S
2325	TOK	above		above\P
##	TAG	<num>
2326	TOK	800		800\X
##	TAG	</num>
##	TAG	<na type="function">
2327	TOK	IU/L		noanat\W
##	TAG	</na>
2328	TOK	in		in\P
2329	TOK	xxx		noanat\W
##	TAG	<foreign lang="LA" pos="P">
2330	TOK	versus		versus\P
##	TAG	</foreign>
2331	TOK	xxx		noanat\W
---	DLD	;		=\DELIM
2332	TOK	and		and\CC
2333	TOK	fasting		fast\VMG----
2334	TOK	serum		serum\N5S
2335	TOK	triglycerides		triglyceride\N5P
2336	TOK	above		above\P
2337	TOK	xxx		noanat\W
2338	TOK	mmol/L		mmol/L\N5S
2339	TOK	in		in\P
2340	TOK	xxx		noanat\W
##	TAG	<foreign lang="LA" pos="P">
2341	TOK	versus		versus\P
##	TAG	</foreign>
2342	TOK	xxx		noanat\W
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
2343	TOK	By	BOS	by\P
2344	TOK	contrast		contrast\VMI----
---	DLD	,		=\DELIM
2345	TOK	haematological		haematological\JA
2346	TOK	abnormalities		abnormality\N5P
2347	TOK	were		be\V6F-A66
2348	TOK	less		less\DDC7
2349	TOK	frequent		frequent\JA
2350	TOK	in		in\P
2351	TOK	the		the\AT---6
2352	TOK	ritonavir		ritonavir\N5S
2353	TOK	group		group\N5S
2354	TOK	than		than\CS
2355	TOK	in		in\P
2356	TOK	the		the\AT---6
##	TAG	<foreign lang="LA" pos="N5S">
2357	TOK	placebo		placebo\N5S
##	TAG	</foreign>
2358	TOK	group		group\VMF6R66
---	DLD	:		=\DELIM
2359	TOK	anaemia		anaemia\N5S
---	DLE	(		=\DELIM
2360	TOK	packed		pack\VMF6A66
---	DLI	-		=\DELIM
2361	TOK	cell		cell\N5S
2362	TOK	volume		volume\N5S
2363	TOK	xxx		noanat\W
---	DLE	)		=\DELIM
2364	TOK	occurred		occur\VMC----
2365	TOK	in		in\P
2366	TOK	xxx		noanat\W
##	TAG	<foreign lang="LA" pos="P">
2367	TOK	versus		versus\P
##	TAG	</foreign>
2368	TOK	xxx		noanat\W
---	DLE	,		=\DELIM
2369	TOK	and		and\CC
2370	TOK	neutropenia		neutropenia\N5S
---	DLE	(		=\DELIM
2371	TOK	xxx		noanat\W
---	DLE	)		=\DELIM
2372	TOK	in		in\P
2373	TOK	xxx		noanat\W
##	TAG	<foreign lang="LA" pos="P">
2374	TOK	versus		versus\P
##	TAG	</foreign>
2375	TOK	xxx		noanat\W
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<head>
2376	TOK	Discussion	BOS	discussion\N5S
tf	TOK		EOS	=\DELS
##	TAG	</head>
##	TAG	<p>
##	TAG	<s>
2378	TOK	In	BOS	in\P
2379	TOK	this		this\AD---S
2380	TOK	study		study\N5S
2381	TOK	ritonavir		ritonavir\N5S
2382	TOK	reduced		reduce\VMF6A66
2383	TOK	the		the\AT---6
2384	TOK	risk		risk\N5S
2385	TOK	of		of\P
##	TAG	<name>
2386	TOK	AIDS		AIDS\N46
##	TAG	</name>
2387	TOK	complications		complication\N5P
2388	TOK	and		and\CC
2389	TOK	prolonged		prolong\VMF6A66
2390	TOK	survival		survival\N5S
2391	TOK	in		in\P
2392	TOK	patients		patient\N5P
2393	TOK	with		with\P
2394	TOK	advanced		advance\VMC----
##	TAG	<name>
2395	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
2396	TOK	1		1\X
##	TAG	</num>
2397	TOK	disease		disease\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
2398	TOK	The	BOS	the\AT---6
2399	TOK	participants		participant\N5P
2400	TOK	in		in\P
2401	TOK	this		this\AD---S
2402	TOK	large		large\JA
---	DLI	-		=\DELIM
2403	TOK	scale		scale\N5S
2404	TOK	clinical		clinical\JA
2405	TOK	trial		trial\N5S
2406	TOK	were		be\V6F-A66
2407	TOK	representative		representative\JA
2408	TOK	of		of\P
2409	TOK	many		many\AI---P
2410	TOK	patients		patient\N5P
2411	TOK	with		with\P
2412	TOK	advanced		advance\VMC----
##	TAG	<name>
2413	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
2414	TOK	1		1\X
##	TAG	</num>
2415	TOK	disease		disease\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
2416	TOK	The	BOS	the\AT---6
2417	TOK	effectiveness		effectiveness\N5S
2418	TOK	of		of\P
2419	TOK	ritonavir		ritonavir\N5S
2420	TOK	treatment		treatment\N5S
2421	TOK	against		against\P
2422	TOK	disease		disease\N5S
2423	TOK	was		be\V6F-A66
2424	TOK	conservatively		conservatively\DGA7
2425	TOK	estimated		estimate\VMC----
2426	TOK	in		in\P
2427	TOK	terms		term\N5P
2428	TOK	of		of\P
2429	TOK	rigorously		rigorously\DGA7
2430	TOK	confirmed		confirm\VMC----
2431	TOK	clinical		clinical\JA
2432	TOK	outcomes		outcome\N5P
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
2433	TOK	Common	BOS	common\JA
##	TAG	<name>
2434	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
2435	TOK	1		1\X
##	TAG	</num>
---	DLE	-		=\DELIM
2436	TOK	related		relate\VMC----
2437	TOK	disorders		disorder\N5P
2438	TOK	were		be\V6F-A66
2439	TOK	consistently		consistently\DGA7
2440	TOK	less		less\DDC7
2441	TOK	common		common\JA
2442	TOK	as		as\P
2443	TOK	first		first\MOS
2444	TOK	outcomes		outcome\N5P
2445	TOK	in		in\P
2446	TOK	the		the\AT---6
2447	TOK	ritonavir		ritonavir\N5S
2448	TOK	group		group\N5S
2449	TOK	than		than\CS
2450	TOK	in		in\P
2451	TOK	the		the\AT---6
##	TAG	<foreign lang="LA" pos="N5S">
2452	TOK	placebo		placebo\N5S
##	TAG	</foreign>
2453	TOK	group		group\VMF6R66
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
##	TAG	<num>
2454	TOK	Two	BOS	Two\X
##	TAG	</num>
2455	TOK	main		main\JA
2456	TOK	factors		factor\N5P
2457	TOK	may		may\VOFDR66
2458	TOK	have		have\VMI----
2459	TOK	exerted		exert\VMC----
2460	TOK	potential		potential\JA
2461	TOK	bias		bias\N5S
2462	TOK	on		on\P
2463	TOK	the		the\AT---6
2464	TOK	overall		overall\JA
2465	TOK	outcome		outcome\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
2466	TOK	First	BOS	first\MOS
---	DLD	,		=\DELIM
2467	TOK	significantly		significantly\DGA7
2468	TOK	more		many\JC
2469	TOK	patients		patient\N5P
2470	TOK	in		in\P
2471	TOK	the		the\AT---6
2472	TOK	ritonavir		ritonavir\N5S
2473	TOK	group		group\N5S
2474	TOK	than		than\CS
2475	TOK	in		in\P
2476	TOK	the		the\AT---6
##	TAG	<foreign lang="LA" pos="N5S">
2477	TOK	placebo		placebo\N5S
##	TAG	</foreign>
2478	TOK	group		group\N5S
2479	TOK	discontinued		discontinue\VMC----
2480	TOK	study		study\N5S
2481	TOK	medication		medication\N5S
2482	TOK	early		early\JA
2483	TOK	in		in\P
2484	TOK	the		the\AT---6
2485	TOK	trial		trial\N5S
##	TAG	<loc pos="P">
2486	TOK	owing to		owing_to\P
##	TAG	</loc>
2487	TOK	drug		drug\N5S
---	DLI	-		=\DELIM
2488	TOK	related		relate\VMC----
2489	TOK	adverse		adverse\JA
2490	TOK	symptoms		symptom\N5P
---	DLD	;		=\DELIM
2491	TOK	this		this\AD---S
2492	TOK	factor		factor\N5S
2493	TOK	could		can\VOFDA66
2494	TOK	have		have\VMI----
2495	TOK	led		lead\VMC----
2496	TOK	to		to\P
2497	TOK	an		an\AI---S
2498	TOK	underestimate		underestimate\N5S
2499	TOK	of		of\P
2500	TOK	treatment		treatment\N5S
2501	TOK	efficacy		efficacy\N5S
2502	TOK	by		by\P
2503	TOK	the		the\AT---6
2504	TOK	intention		intention\N5S
---	DLI	-		=\DELIM
2505	TOK	to		to\P
---	DLI	-		=\DELIM
2506	TOK	treat		treat\N5S
2507	TOK	analysis		analysis\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
2508	TOK	Second	BOS	second\MOS
---	DLD	,		=\DELIM
2509	TOK	since		since\P
##	TAG	<name>
2510	TOK	CD4		CD4\N46
##	TAG	</name>
---	DLE	-		=\DELIM
2511	TOK	lymphocyte		lymphocyte\N5S
2512	TOK	responses		response\N5P
2513	TOK	were		be\V6F-A66
2514	TOK	not		not\DGA7
2515	TOK	concealed		conceal\VMC----
2516	TOK	from		from\P
2517	TOK	investigators		investigator\N5P
---	DLD	,		=\DELIM
2518	TOK	the		the\AT---6
2519	TOK	provision		provision\N5S
2520	TOK	of		of\P
2521	TOK	open		open\VMI----
---	DLI	-		=\DELIM
2522	TOK	label		label\N5S
2523	TOK	ritonavir		ritonavir\N5S
2524	TOK	treatment		treatment\N5S
2525	TOK	after		after\P
2526	TOK	period		period\N5S
##	TAG	<num>
2527	TOK	1		1\X
##	TAG	</num>
2528	TOK	for		for\P
2529	TOK	patients		patient\N5P
2530	TOK	who		who\RW63N-
2531	TOK	had		have\V6F6A66
##	TAG	<name>
2532	TOK	AIDS		AIDS\N46
##	TAG	</name>
2533	TOK	defining		define\VMG----
2534	TOK	events		event\N5P
2535	TOK	may		may\VOFDR66
2536	TOK	have		have\VMI----
2537	TOK	led		lead\VMC----
2538	TOK	to		to\P
2539	TOK	over		over\P
---	DLI	-		=\DELIM
2540	TOK	reporting		report\VMG----
2541	TOK	of		of\P
2542	TOK	such		such\JA
2543	TOK	events		event\N5P
2544	TOK	in		in\P
2545	TOK	the		the\AT---6
##	TAG	<foreign lang="LA" pos="N5S">
2546	TOK	placebo		placebo\N5S
##	TAG	</foreign>
2547	TOK	group		group\VMF6R66
---	DLD	,		=\DELIM
2548	TOK	resulting		result\VMG----
2549	TOK	in		in\P
2550	TOK	a		a\AI---S
2551	TOK	higher		high\JC
2552	TOK	apparent		apparent\JA
2553	TOK	disease		disease\N5S
2554	TOK	rate		rate\N5S
2555	TOK	in		in\P
2556	TOK	that		that\AD---S
2557	TOK	group		group\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
2558	TOK	However	BOS	however\DGA7
---	DLD	,		=\DELIM
2559	TOK	the		the\AT---6
2560	TOK	most		most\DDS7
2561	TOK	frequent		frequent\JA
2562	TOK	outcome		outcome\N5S
2563	TOK	event		event\N5S
2564	TOK	was		be\V6F-A66
2565	TOK	death		death\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
2566	TOK	Furthermore	BOS	furthermore\DGA7
---	DLD	,		=\DELIM
2567	TOK	the		the\AT---6
2568	TOK	risk		risk\N5S
2569	TOK	of		of\P
2570	TOK	developing		develop\VMG----
2571	TOK	an		an\AI---S
##	TAG	<name>
2572	TOK	AIDS		AIDS\N46
##	TAG	</name>
---	DLE	-		=\DELIM
2573	TOK	defining		define\VMG----
2574	TOK	illness		illness\N5S
2575	TOK	was		be\V6F-A66
2576	TOK	consistently		consistently\DGA7
2577	TOK	reduced		reduce\VMC----
2578	TOK	among		among\P
2579	TOK	expected		expect\VMC----
2580	TOK	disease		disease\N5S
2581	TOK	outcomes		outcome\N5P
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
2582	TOK	If	BOS	if\CS
2583	TOK	such		such\JA
2584	TOK	a		a\AI---S
2585	TOK	reporting		report\VMG----
2586	TOK	bias		bias\N5S
2587	TOK	of		of\P
2588	TOK	primary		primary\JA
2589	TOK	disease		disease\N5S
2590	TOK	endpoints		endpoint\N5P
2591	TOK	had		have\V6F6A66
2592	TOK	occurred		occur\VMC----
---	DLD	,		=\DELIM
2593	TOK	provision		provision\N5S
2594	TOK	of		of\P
2595	TOK	ritonavir		ritonavir\N5S
2596	TOK	during		during\P
2597	TOK	period		period\N5S
##	TAG	<num>
2598	TOK	2		2\X
##	TAG	</num>
2599	TOK	for		for\P
2600	TOK	disease		disease\N5S
2601	TOK	outcomes		outcome\N5P
2602	TOK	and		and\CC
2603	TOK	during		during\P
2604	TOK	period		period\N5S
##	TAG	<num>
2605	TOK	3		3\X
##	TAG	</num>
2606	TOK	for		for\P
2607	TOK	all		all\AG---6
2608	TOK	patients		patient\N5P
2609	TOK	irrespective		irrespective\JA
2610	TOK	of		of\P
2611	TOK	disease		disease\N5S
2612	TOK	status		status\N5S
2613	TOK	would		will\VOFDA66
2614	TOK	have		have\VMI----
2615	TOK	decreased		decrease\VMC----
2616	TOK	the		the\AT---6
2617	TOK	overall		overall\JA
2618	TOK	survival		survival\N5S
2619	TOK	benefit		benefit\N5S
2620	TOK	observed		observe\VMC----
2621	TOK	for		for\P
2622	TOK	ritonavir		ritonavir\N5S
2623	TOK	in		in\P
2624	TOK	the		the\AT---6
2625	TOK	analysis		analysis\N5S
2626	TOK	of		of\P
2627	TOK	all		all\AG---6
2628	TOK	deaths		death\N5P
2629	TOK	from		from\P
2630	TOK	any		any\AG---6
2631	TOK	cause		cause\VMF6R66
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
2632	TOK	Our	BOS	our\APP1N6
2633	TOK	data		data\N56
2634	TOK	may		may\VOFDR66
2635	TOK	represent		represent\VMI----
2636	TOK	the		the\AT---6
2637	TOK	effect		effect\N5S
2638	TOK	of		of\P
2639	TOK	early		early\JA
##	TAG	<foreign lang="LA" pos="P">
2640	TOK	versus		versus\P
##	TAG	</foreign>
2641	TOK	deferred		defer\VMC----
2642	TOK	ritonavir		ritonavir\N5S
2643	TOK	treatment		treatment\N5S
2644	TOK	in		in\P
2645	TOK	this		this\AD---S
2646	TOK	population		population\N5S
2647	TOK	of		of\P
2648	TOK	patients		patient\N5P
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
2649	TOK	Despite	BOS	despite\P
2650	TOK	the		the\AT---6
2651	TOK	early		early\JA
2652	TOK	intolerance		intolerance\N5S
2653	TOK	shown		show\VMC----
2654	TOK	by		by\P
2655	TOK	some		some\AG---6
2656	TOK	patients		patient\N5P
2657	TOK	for		for\P
2658	TOK	ritonavir		ritonavir\N5S
2659	TOK	liquid		liquid\N5S
2660	TOK	solution		solution\N5S
---	DLD	,		=\DELIM
2661	TOK	severe		severe\JA
2662	TOK	adverse		adverse\JA
2663	TOK	events		event\N5P
2664	TOK	were		be\V6F-A66
2665	TOK	infrequent		infrequent\JA
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
2666	TOK	Significant	BOS	significant\JA
2667	TOK	rises		rise\N5P
2668	TOK	in		in\P
2669	TOK	serum		serum\N5S
2670	TOK	concentrations		concentration\N5P
2671	TOK	of		of\P
2672	TOK	hepatocellular		hepatocellular\JA
2673	TOK	enzymes		enzyme\N5P
2674	TOK	and		and\CC
2675	TOK	triglycerides		triglyceride\N5P
2676	TOK	during		during\P
2677	TOK	ritonavir		ritonavir\N5S
2678	TOK	therapy		therapy\N5S
2679	TOK	were		be\V6F-A66
2680	TOK	generally		generally\DGA7
2681	TOK	reversible		reversible\JA
2682	TOK	and		and\CC
2683	TOK	not		not\DGA7
2684	TOK	associated		associate\VMC----
2685	TOK	with		with\P
2686	TOK	clinical		clinical\JA
2687	TOK	symptoms		symptom\N5P
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
2688	TOK	The	BOS	the\AT---6
2689	TOK	benefit		benefit\N5S
2690	TOK	of		of\P
2691	TOK	ritonavir		ritonavir\N5S
2692	TOK	treatment		treatment\N5S
---	DLD	,		=\DELIM
2693	TOK	with		with\P
2694	TOK	a		a\AI---S
2695	TOK	median		median\N5S
2696	TOK	of		of\P
##	TAG	<num>
2697	TOK	14		14\X
##	TAG	</num>
2698	TOK	concurrent		concurrent\JA
2699	TOK	medications		medication\N5P
2700	TOK	on		on\P
2701	TOK	entry		entry\N5S
2702	TOK	to		to\P
2703	TOK	the		the\AT---6
2704	TOK	study		study\N5S
---	DLD	,		=\DELIM
2705	TOK	supports		support\VMFDRS3
2706	TOK	overall		overall\JA
2707	TOK	safety		safety\N5S
2708	TOK	in		in\P
2709	TOK	this		this\AD---S
2710	TOK	setting		set\VMG----
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
2711	TOK	Potentially	BOS	potentially\DGA7
2712	TOK	serious		serious\JA
2713	TOK	drug		drug\N5S
2714	TOK	interactions		interaction\N5P
2715	TOK	are		be\V6FDR66
2716	TOK	suggested		suggest\VMC----
2717	TOK	by		by\P
2718	TOK	expected		expect\VMC----
2719	TOK	or		or\CC
2720	TOK	observed		observe\VMC----
2721	TOK	pharmacokinetic		pharmacokinetic\JA
2722	TOK	interaction		interaction\N5S
2723	TOK	of		of\P
2724	TOK	ritonavir		ritonavir\N5S
2725	TOK	on		on\P
2726	TOK	the		the\AT---6
2727	TOK	metabolism		metabolism\N5S
2728	TOK	of		of\P
2729	TOK	other		other\JA
2730	TOK	drugs		drug\N5P
2731	TOK	through		through\P
2732	TOK	the		the\AT---6
2733	TOK	enteric		enteric\JA
2734	TOK	and		and\CC
2735	TOK	hepatic		hepatic\JA
2736	TOK	microsomal		microsomal\JA
2737	TOK	cytochrome		cytochrome\N5S
##	TAG	<name>
2738	TOK	P450		P450\N46
##	TAG	</name>
2739	TOK	3A4		3A4\N5P
2740	TOK	metabolic		metabolic\JA
2741	TOK	pathway		pathway\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
2742	TOK	This	BOS	this\AD---S
2743	TOK	trial		trial\N5S
2744	TOK	excluded		exclude\VMC----
2745	TOK	medications		medication\N5P
2746	TOK	based		base\VMC----
2747	TOK	on		on\P
2748	TOK	theoretical		theoretical\JA
2749	TOK	risks		risk\N5P
2750	TOK	of		of\P
2751	TOK	potential		potential\JA
2752	TOK	drug		drug\N5S
2753	TOK	interactions		interaction\N5P
---	DLD	;		=\DELIM
2754	TOK	however		however\DGA7
---	DLD	,		=\DELIM
2755	TOK	rifabutin		rifabutin\N5S
2756	TOK	therapy		therapy\N5S
2757	TOK	was		be\V6F-A66
2758	TOK	allowed		allow\VMC----
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
##	TAG	<name>
2759	TOK	Rifabutin	BOS	Rifabutin\N46
##	TAG	</name>
2760	TOK	was		be\V6F-A66
2761	TOK	the		the\AT---6
2762	TOK	only		only\JA
2763	TOK	agent		agent\N5S
2764	TOK	associated		associate\VMC----
2765	TOK	with		with\P
2766	TOK	increased		increase\VMC----
2767	TOK	adverse		adverse\JA
2768	TOK	events		event\N5P
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
2769	TOK	The	BOS	the\AT---6
2770	TOK	effectiveness		effectiveness\N5S
2771	TOK	of		of\P
2772	TOK	anti		anti\JA
---	DLD	-		=\DELIM
##	TAG	<name>
2773	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
2774	TOK	1		1\X
##	TAG	</num>
2775	TOK	therapy		therapy\N5S
2776	TOK	is		be\V6FDRS3
2777	TOK	reflected		reflect\VMC----
2778	TOK	in		in\P
2779	TOK	treatment		treatment\N5S
2780	TOK	responses		response\N5P
2781	TOK	of		of\P
##	TAG	<name>
2782	TOK	CD4		CD4\N46
##	TAG	</name>
2783	TOK	lymphocytes		lymphocyte\N5P
2784	TOK	and		and\CC
2785	TOK	plasma		plasma\N5S
2786	TOK	viraemia		viraemia\N5S
---	DLD	;		=\DELIM
2787	TOK	the		the\AT---6
2788	TOK	previously		previously\DGA7
2789	TOK	reported		report\VMC----
2790	TOK	responses		response\N5P
2791	TOK	to		to\P
2792	TOK	ritonavir		ritonavir\N5S
2793	TOK	treatment		treatment\N5S
2794	TOK	were		be\V6F-A66
2795	TOK	confirmed		confirm\VMC----
2796	TOK	in		in\P
2797	TOK	this		this\AD---S
2798	TOK	trial		trial\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
2799	TOK	The	BOS	the\AT---6
2800	TOK	reported		report\VMC----
2801	TOK	response		response\N5S
2802	TOK	of		of\P
##	TAG	<name>
2803	TOK	CD8		CD8\N46
##	TAG	</name>
2804	TOK	lymphocytes		lymphocyte\N5P
2805	TOK	was		be\V6F-A66
2806	TOK	also		also\DGA7
2807	TOK	confirmed		confirm\VMF6A66
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
##	TAG	<name>
2808	TOK	CD8	BOS	CD8\N46
##	TAG	</name>
2809	TOK	lymphocytes		lymphocyte\N5P
2810	TOK	and		and\CC
##	TAG	<name>
2811	TOK	CD8		CD8\N46
##	TAG	</name>
---	DLE	-		=\DELIM
2812	TOK	secreted		secrete\VMC----
2813	TOK	factors		factor\N5P
2814	TOK	may		may\VOFDR66
2815	TOK	be		be\VMI----
2816	TOK	involved		involve\VMC----
2817	TOK	in		in\P
2818	TOK	the		the\AT---6
2819	TOK	host		host\N5S
2820	TOK	response		response\N5S
2821	TOK	to		to\P
##	TAG	<name>
2822	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
2823	TOK	1		1\X
##	TAG	</num>
2824	TOK	infection		infection\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
2825	TOK	The	BOS	the\AT---6
2826	TOK	changes		change\N5P
2827	TOK	in		in\P
##	TAG	<name>
2828	TOK	CD8		CD8\N46
##	TAG	</name>
2829	TOK	lymphocyte		lymphocyte\N5S
2830	TOK	counts		count\N5P
2831	TOK	during		during\P
2832	TOK	ritonavir		ritonavir\N5S
2833	TOK	treatment		treatment\N5S
2834	TOK	may		may\VOFDR66
2835	TOK	also		also\DGA7
2836	TOK	represent		represent\VMI----
2837	TOK	either		either\CC
2838	TOK	a		a\AI---S
2839	TOK	direct		direct\JA
2840	TOK	effect		effect\N5S
2841	TOK	or		or\CC
2842	TOK	a		a\AI---S
2843	TOK	therapeutic		therapeutic\JA
2844	TOK	effect		effect\N5S
2845	TOK	in		in\P
2846	TOK	which		which\RW63N-
2847	TOK	the		the\AT---6
2848	TOK	initial		initial\JA
2849	TOK	rise		rise\N5S
2850	TOK	and		and\CC
2851	TOK	subsequent		subsequent\JA
2852	TOK	decline		decline\N5S
2853	TOK	from		from\P
2854	TOK	peak		peak\N5S
2855	TOK	response		response\N5S
2856	TOK	on		on\P
2857	TOK	potent		potent\JA
2858	TOK	therapy		therapy\N5S
2859	TOK	may		may\VOFDR66
2860	TOK	reflect		reflect\VMI----
2861	TOK	lower		low\JC
##	TAG	<name>
2862	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
2863	TOK	1		1\X
##	TAG	</num>
2864	TOK	replication		replication\N5S
2865	TOK	and		and\CC
2866	TOK	subsequent		subsequent\JA
2867	TOK	decreased		decrease\VMF6A66
2868	TOK	immune		immune\JA
2869	TOK	activation		activation\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
2870	TOK	Since	BOS	since\CS
2871	TOK	initial		initial\JA
2872	TOK	reporting		report\VMG----
2873	TOK	of		of\P
2874	TOK	this		this\AD---S
2875	TOK	study		study\N5S
2876	PGR	's		genmark\GENMARK
2877	TOK	results		result\N5P
2878	TOK	and		and\CC
##	TAG	<name>
2879	TOK	US		US\N46
##	TAG	</name>
2880	TOK	licensing		licensing\N5S
2881	TOK	of		of\P
2882	TOK	ritonavir		ritonavir\N5S
---	DLD	,		=\DELIM
2883	TOK	controlled		control\VMC----
2884	TOK	trials		trial\N5P
2885	TOK	have		have\V6F6R66
2886	TOK	been		be\VMC----
2887	TOK	continued		continue\VMC----
2888	TOK	or		or\CC
2889	TOK	started		start\VMC----
2890	TOK	to		to\P
2891	TOK	confirm		confirm\VMI----
2892	TOK	the		the\AT---6
2893	TOK	clinical		clinical\JA
2894	TOK	benefit		benefit\N5S
2895	TOK	of		of\P
2896	TOK	a		a\AI---S
2897	TOK	protease		protease\N5S
2898	TOK	inhibitor		inhibitor\N5S
2899	TOK	on		on\P
2900	TOK	health		health\N5S
2901	TOK	and		and\CC
2902	TOK	life		life\N5S
2903	TOK	in		in\P
##	TAG	<name>
2904	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
2905	TOK	1		1\X
##	TAG	</num>
2906	TOK	disease		disease\N5S
2907	TOK	and		and\CC
##	TAG	<name>
2908	TOK	AIDS		AIDS\N46
##	TAG	</name>
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
2909	TOK	The	BOS	the\AT---6
2910	TOK	need		need\N5S
2911	TOK	to		to\P
2912	TOK	prove		prove\VMI----
2913	TOK	successively		successively\DGA7
2914	TOK	the		the\AT---6
2915	TOK	effectiveness		effectiveness\N5S
2916	TOK	of		of\P
2917	TOK	individual		individual\JA
2918	TOK	drugs		drug\N5P
2919	TOK	of		of\P
2920	TOK	a		a\AI---S
2921	TOK	class		class\N5S
---	DLD	,		=\DELIM
##	TAG	<loc pos="JA">
2922	TOK	as opposed to		as_opposed_to\JA
##	TAG	</loc>
2923	TOK	their		their\APP3N6
2924	TOK	comparative		comparative\JA
2925	TOK	safety		safety\N5S
---	DLD	,		=\DELIM
2926	TOK	activity		activity\N5S
---	DLD	,		=\DELIM
2927	TOK	and		and\CC
2928	TOK	efficacy		efficacy\N5S
---	DLD	,		=\DELIM
2929	TOK	must		must\VOFDR66
2930	TOK	be		be\VMI----
2931	TOK	balanced		balance\VMC----
2932	TOK	against		against\P
2933	TOK	the		the\AT---6
2934	TOK	rights		right\N5P
2935	TOK	of		of\P
2936	TOK	human		human\JA
2937	TOK	trial		trial\N5S
2938	TOK	volunteers		volunteer\N5P
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
2939	TOK	This	BOS	this\AD---S
2940	TOK	ethical		ethical\JA
2941	TOK	issue		issue\N5S
2942	TOK	becomes		become\VMFDRS3
2943	TOK	increasingly		increasingly\DGA7
2944	TOK	important		important\JA
2945	TOK	as		as\P
2946	TOK	guidelines		guideline\N5P
2947	TOK	on		on\P
2948	TOK	treatment		treatment\N5S
2949	TOK	standards		standard\N5P
2950	TOK	become		become\VMF6R66
2951	TOK	established		establish\VMF6A66
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
2952	TOK	Although	BOS	although\CS
2953	TOK	ritonavir		ritonavir\N5S
2954	TOK	was		be\V6F-A66
2955	TOK	the		the\AT---6
2956	TOK	first		first\MOS
2957	TOK	protease		protease\N5S
2958	TOK	inhibitor		inhibitor\N5S
2959	TOK	for		for\P
2960	TOK	which		which\RW63N-
2961	TOK	clinical		clinical\JA
2962	TOK	benefit		benefit\N5S
2963	TOK	was		be\V6F-A66
2964	TOK	demonstrated		demonstrate\VMC----
---	DLD	,		=\DELIM
2965	TOK	understanding		understanding\N5S
2966	TOK	of		of\P
2967	TOK	the		the\AT---6
2968	TOK	clinical		clinical\JA
2969	TOK	correlation		correlation\N5S
2970	TOK	of		of\P
2971	TOK	changes		change\N5P
2972	TOK	in		in\P
##	TAG	<name>
2973	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
2974	TOK	1		1\X
##	TAG	</num>
##	TAG	<name>
2975	TOK	RNA		RNA\N46
##	TAG	</name>
2976	TOK	concentrations		concentration\N5P
2977	TOK	and		and\CC
2978	TOK	counts		count\N5P
2979	TOK	of		of\P
##	TAG	<name>
2980	TOK	CD4		CD4\N46
##	TAG	</name>
2981	TOK	and		and\CC
##	TAG	<name>
2982	TOK	CD8		CD8\N46
##	TAG	</name>
2983	TOK	lymphocytes		lymphocyte\N5P
2984	TOK	requires		require\VMFDRS3
2985	TOK	further		further\JA
2986	TOK	analysis		analysis\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
2987	TOK	A	BOS	a\AI---S
2988	TOK	greater		great\JC
2989	TOK	and		and\CC
2990	TOK	more		more\DDC7
2991	TOK	sustained		sustain\VMC----
2992	TOK	suppression		suppression\N5S
2993	TOK	of		of\P
##	TAG	<name>
2994	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
2995	TOK	1		1\X
##	TAG	</num>
##	TAG	<name>
2996	TOK	RNA		RNA\N46
##	TAG	</name>
2997	TOK	than		than\CS
2998	TOK	seen		see\VMC----
2999	TOK	in		in\P
3000	TOK	this		this\AD---S
3001	TOK	study		study\N5S
3002	TOK	was		be\V6F-A66
3003	TOK	reported		report\VMC----
3004	TOK	in		in\P
3005	TOK	patients		patient\N5P
3006	TOK	with		with\P
3007	TOK	less		less\DDC7
3008	TOK	advanced		advance\VMC----
##	TAG	<name>
3009	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
3010	TOK	1		1\X
##	TAG	</num>
---	DLE	-		=\DELIM
3011	TOK	related		relate\VMC----
3012	TOK	immunodeficency		immunodeficency\N5S
3013	TOK	and		and\CC
3014	TOK	when		when\CS
3015	TOK	zalcitabine		zalcitabine\N5S
3016	TOK	and		and\CC
3017	TOK	zidovudine		zidovudine\N5S
3018	TOK	were		be\V6F-A66
3019	TOK	given		give\VMC----
3020	TOK	together		together\DGA7
3021	TOK	with		with\P
3022	TOK	ritonavir		ritonavir\N5S
3023	TOK	as		as\P
3024	TOK	initial		initial\JA
3025	TOK	therapy		therapy\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
3026	TOK	Preliminary	BOS	preliminary\JA
3027	TOK	results		result\N5P
3028	TOK	from		from\P
3029	TOK	continuing		continuing\JA
3030	TOK	studies		study\N5P
3031	TOK	have		have\V6F6R66
3032	TOK	shown		show\VMC----
3033	TOK	suppression		suppression\N5S
3034	TOK	of		of\P
##	TAG	<name>
3035	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
3036	TOK	1		1\X
##	TAG	</num>
##	TAG	<name>
3037	TOK	RNA		RNA\N46
##	TAG	</name>
3038	TOK	below		below\P
3039	TOK	standard		standard\JA
3040	TOK	quantification		quantification\N5S
3041	TOK	values		value\N5P
3042	TOK	with		with\P
3043	TOK	ritonavir		ritonavir\N5S
3044	TOK	plus		plus\CS
3045	TOK	saquinavir		saquinavir\N5S
3046	TOK	or		or\CC
3047	TOK	plus		plus\CS
3048	TOK	zidovudine		zidovudine\N5S
3049	TOK	and		and\CC
3050	TOK	lamivudine		lamivudine\N5S
3051	TOK	in		in\P
3052	TOK	the		the\AT---6
3053	TOK	majority		majority\N5S
3054	TOK	of		of\P
3055	TOK	patients		patient\N5P
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3056	TOK	This	BOS	this\AD---S
3057	TOK	study		study\N5S
3058	TOK	used		use\VMF6A66
3059	TOK	the		the\AT---6
3060	TOK	design		design\N5S
3061	TOK	of		of\P
3062	TOK	adding		add\VMG----
3063	TOK	ritonavir		ritonavir\N5S
3064	TOK	to		to\P
3065	TOK	at		at\P
3066	TOK	most		most\AG---6
##	TAG	<num>
3067	TOK	two		two\X
##	TAG	</num>
3068	TOK	licensed		license\VMC----
3069	TOK	nucleoside		nucleoside\N5S
3070	TOK	antiretroviral		antiretroviral\JA
3071	TOK	agents		agent\N5P
3072	TOK	as		as\CS
3073	TOK	tolerated		tolerate\VMC----
3074	TOK	by		by\P
3075	TOK	individual		individual\JA
3076	TOK	patients		patient\N5P
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
3077	TOK	This	BOS	this\AD---S
3078	TOK	strategy		strategy\N5S
3079	TOK	was		be\V6F-A66
3080	TOK	then		then\DGA7
3081	TOK	consistent		consistent\JA
3082	TOK	with		with\P
3083	TOK	common		common\JA
3084	TOK	clinical		clinical\JA
3085	TOK	practice		practice\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
3086	TOK	In	BOS	in\P
3087	TOK	patients		patient\N5P
3088	TOK	with		with\P
3089	TOK	extensive		extensive\JA
3090	TOK	previous		previous\JA
3091	TOK	therapy		therapy\N5S
3092	TOK	and		and\CC
3093	TOK	advanced		advance\VMC----
3094	TOK	immunodeficiency		immunodeficiency\N5S
---	DLD	,		=\DELIM
3095	TOK	the		the\AT---6
3096	TOK	approach		approach\N5S
3097	TOK	of		of\P
3098	TOK	adding		add\VMG----
3099	TOK	a		a\AI---S
3100	TOK	single		single\JA
3101	TOK	new		new\JA
3102	TOK	agent		agent\N5S
3103	TOK	simulates		simulate\VMFDRS3
3104	TOK	monotherapy		monotherapy\N5S
3105	TOK	with		with\P
3106	TOK	that		that\AD---S
3107	TOK	agent		agent\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
3108	TOK	The	BOS	the\AT---6
3109	TOK	pattern		pattern\N5S
3110	TOK	of		of\P
3111	TOK	incomplete		incomplete\JA
3112	TOK	and		and\CC
3113	TOK	transient		transient\JA
3114	TOK	suppression		suppression\N5S
3115	TOK	of		of\P
##	TAG	<name>
3116	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
3117	TOK	1		1\X
##	TAG	</num>
##	TAG	<name>
3118	TOK	RNA		RNA\N46
##	TAG	</name>
3119	TOK	observed		observe\VMC----
3120	TOK	in		in\P
3121	TOK	this		this\AD---S
3122	TOK	study		study\N5S
3123	TOK	is		be\V6FDRS3
3124	TOK	similar		similar\JA
3125	TOK	to		to\P
3126	TOK	that		that\RDS3N-
3127	TOK	in		in\P
3128	TOK	other		other\JA
3129	TOK	studies		study\N5P
3130	TOK	of		of\P
3131	TOK	ritonavir		ritonavir\N5S
3132	TOK	monotherapy		monotherapy\N5P
---	DLD	,		=\DELIM
3133	TOK	in		in\P
3134	TOK	which		which\RW63N-
3135	TOK	stepwise		stepwise\JA
##	TAG	<name>
3136	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
3137	TOK	1		1\X
##	TAG	</num>
3138	TOK	drug		drug\N5S
3139	TOK	resistance		resistance\N5S
3140	TOK	emerged		emerge\VMF6A66
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
3141	TOK	The	BOS	the\AT---6
3142	TOK	apparently		apparently\DGA7
3143	TOK	greater		great\JC
3144	TOK	efficacy		efficacy\N5S
3145	TOK	of		of\P
3146	TOK	ritonavir		ritonavir\N5S
3147	TOK	in		in\P
3148	TOK	patients		patient\N5P
3149	TOK	with		with\P
3150	TOK	higher		high\JC
3151	TOK	baseline		baseline\N5S
##	TAG	<name>
3152	TOK	CD4		CD4\N46
##	TAG	</name>
---	DLE	-		=\DELIM
3153	TOK	lymphocyte		lymphocyte\N5S
3154	TOK	counts		count\N5P
3155	TOK	and		and\CC
3156	TOK	in		in\P
3157	TOK	patients		patient\N5P
3158	TOK	taking		take\VMG----
##	TAG	<loc pos="DGA7">
3159	TOK	at least		at_least\DGA7
##	TAG	</loc>
3160	TOK	one		one\MCS
3161	TOK	other		other\JA
3162	TOK	anti		anti\JA
---	DLD	-		=\DELIM
##	TAG	<name>
3163	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
3164	TOK	1		1\X
##	TAG	</num>
3165	TOK	medication		medication\N5S
3166	TOK	at		at\P
3167	TOK	baseline		baseline\N5S
3168	TOK	may		may\VOFDR66
3169	TOK	reflect		reflect\VMI----
3170	TOK	the		the\AT---6
3171	TOK	better		better\DDC7
3172	TOK	general		general\JA
3173	TOK	health		health\N5S
3174	TOK	or		or\CC
3175	TOK	tolerance		tolerance\N5S
3176	TOK	of		of\P
3177	TOK	ritonavir		ritonavir\N5S
3178	TOK	in		in\P
3179	TOK	these		this\AD---P
3180	TOK	patients		patient\N5P
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
3181	TOK	However	BOS	however\DGA7
---	DLD	,		=\DELIM
3182	TOK	it		it\RPS3N6
3183	TOK	may		may\VOFDR66
3184	TOK	also		also\DGA7
3185	TOK	represent		represent\VMI----
3186	TOK	increased		increase\VMC----
3187	TOK	and		and\CC
3188	TOK	more		more\DDC7
3189	TOK	durable		durable\JA
3190	TOK	anti		anti\JA
---	DLD	-		=\DELIM
##	TAG	<name>
3191	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
3192	TOK	1		1\X
##	TAG	</num>
3193	TOK	activity		activity\N5S
3194	TOK	or		or\CC
3195	TOK	greater		great\JC
3196	TOK	efficacy		efficacy\N5S
3197	TOK	of		of\P
3198	TOK	ritonavir		ritonavir\N5S
3199	TOK	therapy		therapy\N5S
3200	TOK	in		in\P
3201	TOK	earlier		early\JC
3202	TOK	combination		combination\N5S
3203	TOK	as		as\P
3204	TOK	a		a\AI---S
3205	TOK	result		result\N5S
3206	TOK	of		of\P
3207	TOK	decreased		decrease\VMC----
3208	TOK	or		or\CC
3209	TOK	delayed		delay\VMC----
3210	TOK	drug		drug\N5S
3211	TOK	resistance		resistance\N5S
3212	TOK	afforded		afford\VMC----
3213	TOK	by		by\P
3214	TOK	combination		combination\N5S
3215	TOK	therapy		therapy\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3216	TOK	This	BOS	this\AD---S
3217	TOK	trial		trial\N5S
3218	TOK	showed		show\VMF6A66
3219	TOK	the		the\AT---6
3220	TOK	efficacy		efficacy\N5S
3221	TOK	of		of\P
3222	TOK	ritonavir		ritonavir\N5S
3223	TOK	in		in\P
3224	TOK	treatment		treatment\N5S
3225	TOK	of		of\P
3226	TOK	heavily		heavily\DGA7
3227	TOK	pretreated		pretreat\VMC----
3228	TOK	patients		patient\N5P
3229	TOK	with		with\P
3230	TOK	advanced		advance\VMC----
##	TAG	<name>
3231	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
3232	TOK	1		1\X
##	TAG	</num>
3233	TOK	disease		disease\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
3234	TOK	The	BOS	the\AT---6
3235	TOK	tactic		tactic\N5S
3236	TOK	of		of\P
3237	TOK	adding		add\VMG----
3238	TOK	a		a\AI---S
3239	TOK	single		single\JA
3240	TOK	potent		potent\JA
3241	TOK	anti		anti\JA
---	DLD	-		=\DELIM
##	TAG	<name>
3242	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
3243	TOK	1		1\X
##	TAG	</num>
3244	TOK	drug		drug\N5S
3245	TOK	to		to\P
3246	TOK	a		a\AI---S
3247	TOK	stable		stable\JA
3248	TOK	or		or\CC
3249	TOK	failing		fail\VMG----
3250	TOK	underlying		underlying\JA
3251	TOK	treatment		treatment\N5S
3252	TOK	in		in\P
3253	TOK	a		a\AI---S
3254	TOK	clinical		clinical\JA
3255	TOK	trial		trial\N5S
3256	TOK	may		may\VOFDR66
3257	TOK	be		be\VMI----
3258	TOK	improved		improve\VMC----
3259	TOK	upon		upon\P
3260	TOK	in		in\P
3261	TOK	clinical		clinical\JA
3262	TOK	practice		practice\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
3263	TOK	Further	BOS	further\JA
3264	TOK	studies		study\N5P
3265	TOK	should		shall\VOFDA66
3266	TOK	assess		assess\VMI----
3267	TOK	whether		whether\CS
3268	TOK	initial		initial\JA
3269	TOK	combination		combination\N5S
3270	TOK	treatment		treatment\N5S
3271	TOK	with		with\P
3272	TOK	ritonavir		ritonavir\N5S
3273	TOK	and		and\CC
3274	TOK	other		other\JA
3275	TOK	antiretroviral		antiretroviral\JA
3276	TOK	agents		agent\N5P
3277	TOK	or		or\CC
3278	TOK	the		the\AT---6
3279	TOK	simultaneous		simultaneous\JA
3280	TOK	change		change\N5S
3281	TOK	of		of\P
##	TAG	<num>
3282	TOK	two		two\X
##	TAG	</num>
3283	TOK	or		or\CC
3284	TOK	more		more\DDC7
3285	TOK	anti		anti\JA
---	DLD	-		=\DELIM
##	TAG	<name>
3286	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
3287	TOK	1		1\X
##	TAG	</num>
3288	TOK	drugs		drug\N5P
3289	TOK	will		will\VOFDR66
##	TAG	<foreign lang="LA" pos="VMF6R66">
3290	TOK	confer		confer\VMF6R66
##	TAG	</foreign>
3291	TOK	greater		great\JC
3292	TOK	and		and\CC
3293	TOK	more		more\DDC7
3294	TOK	durable		durable\JA
3295	TOK	clinical		clinical\JA
3296	TOK	benefit		benefit\N5S
3297	TOK	than		than\CS
3298	TOK	measured		measure\VMC----
3299	TOK	here		here\DGA7
---	DLD	,		=\DELIM
3300	TOK	as		as\DGA7
3301	TOK	promised		promise\VMC----
3302	TOK	by		by\P
3303	TOK	surrogate		surrogate\N5S
3304	TOK	marker		marker\N5S
3305	TOK	studies		study\N5P
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<head>
3306	TOK	Table	BOS	table\VMF6R66
##	TAG	<num>
3307	TOK	1	EOS	1\X
##	TAG	</num>
##	TAG	</head>
##	TAG	<head>
3309	TOK	Baseline	BOS	baseline\N5S
3310	TOK	demographic		demographic\JA
3311	TOK	and		and\CC
3312	TOK	clinical		clinical\JA
3313	TOK	characteristics	EOS	characteristic\N5P
##	TAG	</head>
##	TAG	<p>
##	TAG	<s>
3315	TOK	Demography	BOS	demography\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
##	TAG	<name>
3316	TOK	M/F	BOS	M/F\N46
##	TAG	</name>
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3317	TOK	Median	BOS	median\N5S
---	DLE	(		=\DELIM
3318	TOK	range		range\VMF6R66
---	DLD	)		=\DELIM
3319	TOK	age		age\N5S
3320	TOK	in		in\P
3321	TOK	years		year\N5P
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
##	TAG	<name>
3322	TOK	White/non	BOS	White/non\N46
##	TAG	</name>
---	DLE	-		=\DELIM
3323	TOK	white		white\JA
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
##	TAG	<name>
3324	TOK	HIV	BOS	HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
3325	TOK	1		1\X
##	TAG	</num>
3326	TOK	risk		risk\N5S
3327	TOK	factor		factor\N5S
---	DLE	(		=\DELIM
3328	TOK	number		number\N5S
3329	TOK	of		of\P
3330	TOK	patients		patient\N5P
---	DLD	)		=\DELIM
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3331	TOK	Male	BOS	male\N5S
3332	TOK	homosexual		homosexual\JA
3333	TOK	or		or\CC
3334	TOK	bisexual		bisexual\JA
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3335	TOK	Heterosexual	BOS	heterosexual\JA
---	DLD	,		=\DELIM
3336	TOK	sex		sex\N5S
3337	TOK	partner		partner\N5S
##	TAG	<name>
3338	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
3339	TOK	1		1\X
##	TAG	</num>
---	DLE	-		=\DELIM
3340	TOK	positive		positive\JA
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3341	TOK	Injection	BOS	injection\N5S
---	DLI	-		=\DELIM
3342	TOK	drug		drug\N5S
3343	TOK	user		user\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3344	TOK	Sex	BOS	sex\N5S
3345	TOK	partner		partner\N5S
3346	TOK	injection		injection\N5S
---	DLI	-		=\DELIM
3347	TOK	drug		drug\N5S
3348	TOK	user		user\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3349	TOK	Transfusion	BOS	transfusion\N5S
3350	TOK	recipient		recipient\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
##	TAG	<name>
3351	TOK	Haemophiliac	BOS	Haemophiliac\N46
##	TAG	</name>
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3352	TOK	Other	BOS	other\JA
3353	TOK	or		or\CC
3354	TOK	unknown		unknown\JA
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
##	TAG	<name>
3355	TOK	Karnofsky	BOS	Karnofsky\N46
##	TAG	</name>
3356	TOK	performance		performance\N5S
3357	TOK	score		score\N56
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
##	TAG	<name>
3358	TOK	HIV	BOS	HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
3359	TOK	1		1\X
##	TAG	</num>
3360	TOK	history		history\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3361	TOK	Time	BOS	time\N5S
3362	TOK	since		since\P
##	TAG	<name>
3363	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
3364	TOK	1		1\X
##	TAG	</num>
3365	TOK	diagnosis		diagnosis\N5S
---	DLE	(		=\DELIM
3366	TOK	years		year\N5P
---	DLD	)		=\DELIM
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3367	TOK	Duration	BOS	duration\N5S
3368	TOK	of		of\P
3369	TOK	antiretroviral		antiretroviral\JA
3370	TOK	treatment		treatment\N5S
---	DLE	(		=\DELIM
3371	TOK	years		year\N5P
---	DLD	)		=\DELIM
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3372	TOK	Duration	BOS	duration\N5S
3373	TOK	of		of\P
3374	TOK	zidovudine		zidovudine\N5S
3375	TOK	treatment		treatment\N5S
---	DLE	(		=\DELIM
3376	TOK	years		year\N5P
---	DLD	)		=\DELIM
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3377	TOK	Mean	BOS	mean\JA
3378	TOK	number		number\N5S
3379	TOK	of		of\P
3380	TOK	antiretroviral		antiretroviral\JA
3381	TOK	drugs		drug\N5P
3382	TOK	used		use\VMF6A66
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
##	TAG	<name>
3383	TOK	CD4	BOS	CD4\N46
##	TAG	</name>
---	DLE	-		=\DELIM
3384	TOK	lymphocyte		lymphocyte\N5S
3385	TOK	count		count\VMF6R66
---	DLE	(		=\DELIM
3386	TOK	number		number\N5S
3387	TOK	of		of\P
3388	TOK	patients		patient\N5P
---	DLD	)		=\DELIM
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3389	TOK	Missing	BOS	miss\VMG----
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3390	TOK	Lymphocyte	BOS	lymphocyte\N5S
3391	TOK	count		count\VMF6R66
---	DLE	(		=\DELIM
3392	TOK	per		per\P
3393	TOK	xxx		noanat\W
---	DLE	)		=\DELIM
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
##	TAG	<name>
3395	TOK	CD4	BOS	CD4\N46
##	TAG	</name>
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
##	TAG	<name>
3396	TOK	CD8	BOS	CD8\N46
##	TAG	</name>
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3397	TOK	Plasma	BOS	plasma\N5S
##	TAG	<name>
3398	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
3399	TOK	1		1\X
##	TAG	</num>
##	TAG	<name>
3400	TOK	RNA		RNA\N46
##	TAG	</name>
3401	TOK	load		load\VMF6R66
---	DLE	(		=\DELIM
3402	TOK	log10		log10\JA
3403	TOK	copies/mL		copies/mL\N5P
---	DLE	)		=\DELIM
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3405	TOK	Antiviral	BOS	antiviral\JA
3406	TOK	activity		activity\N5S
3407	TOK	subset		subset\N5S
3408	TOK	n		n\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3409	TOK	Median	BOS	median\N5S
---	DLE	(		=\DELIM
##	TAG	<name>
3410	TOK	IQR		IQR\N46
##	TAG	</name>
---	DLE	)		=\DELIM
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3412	TOK	All	BOS	all\AG---6
3413	TOK	patients		patient\N5P
3414	TOK	tested		test\VMF6A66
3415	TOK	n		n\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3416	TOK	Median	BOS	median\N5S
---	DLE	(		=\DELIM
##	TAG	<name>
3417	TOK	IQR		IQR\N46
##	TAG	</name>
---	DLE	)		=\DELIM
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3419	TOK	Baseline	BOS	baseline\N5S
3420	TOK	concurrent		concurrent\JA
3421	TOK	treatment		treatment\N5S
3422	TOK	taken		take\VMC----
3423	TOK	by		by\P
##	TAG	<loc pos="DGA7">
3424	TOK	at least		at_least\DGA7
##	TAG	</loc>
##	TAG	<na type="function">
3425	TOK	15% of		noanat\W
##	TAG	</na>
3426	TOK	patients		patient\N5P
3427	TOK	in		in\P
3428	TOK	either		either\CC
3429	TOK	group		group\VMF6R66
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3430	TOK	Zidovudine	BOS	zidovudine\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3431	TOK	Stavudine	BOS	stavudine\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3432	TOK	Zalcitabine	BOS	zalcitabine\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3433	TOK	Didanosine	BOS	didanosine\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3434	TOK	Trimethoprim	BOS	trimethoprim\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
##	TAG	<name>
3435	TOK	Sulphamethoxazole	BOS	Sulphamethoxazole\N46
##	TAG	</name>
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
##	TAG	<name>
3436	TOK	Clarithromycin	BOS	Clarithromycin\N46
##	TAG	</name>
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
##	TAG	<name>
3437	TOK	Rifabutin	BOS	Rifabutin\N46
##	TAG	</name>
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3438	TOK	Pentamidine	BOS	pentamidine\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3439	TOK	Ciprofloxacin	BOS	ciprofloxacin\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3440	TOK	Fluconazole	BOS	fluconazole\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3441	TOK	Acyclovir	BOS	acyclovir\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3442	TOK	Paracetamol	BOS	paracetamol\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3443	TOK	Ascorbic	BOS	ascorbic\N5S
3444	TOK	acid		acid\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3445	TOK	Testosterone	BOS	testosterone\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3446	TOK	Loperamide	BOS	loperamide\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
##	TAG	<name>
3447	TOK	Filgrastim	BOS	Filgrastim\N46
##	TAG	</name>
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<head>
3448	TOK	Figure	BOS	figure\N5S
##	TAG	<num>
3449	TOK	1	EOS	1\X
##	TAG	</num>
##	TAG	</head>
##	TAG	<head>
3451	TOK	Trial	BOS	trial\N5S
3452	TOK	profile	EOS	profile\N5S
##	TAG	</head>
##	TAG	<p>
##	TAG	<s>
3454	TOK	In	BOS	in\P
3455	TOK	period		period\N5S
##	TAG	<num>
3456	TOK	2		2\X
##	TAG	</num>
3457	TOK	there		there\DGA7
3458	TOK	is		be\V6FDRS3
3459	TOK	some		some\DGA7
3460	TOK	overlap		overlap\VMI----
3461	TOK	between		between\P
3462	TOK	patients		patient\N5P
3463	TOK	with		with\P
3464	TOK	confirmed		confirm\VMC----
3465	TOK	endpoints		endpoint\N5P
---	DLE	(		=\DELIM
##	TAG	<name>
3466	TOK	AIDS		AIDS\N46
##	TAG	</name>
---	DLE	-		=\DELIM
3467	TOK	defining		define\VMG----
3468	TOK	illness		illness\N5S
3469	TOK	or		or\CC
3470	TOK	death		death\N5S
---	DLD	)		=\DELIM
3471	TOK	and		and\CC
3472	TOK	numbers		number\N5P
3473	TOK	of		of\P
3474	TOK	deaths		death\N5P
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<head>
3475	TOK	Figure	BOS	figure\N5S
##	TAG	<num>
3476	TOK	2	EOS	2\X
##	TAG	</num>
##	TAG	</head>
##	TAG	<head>
3478	TOK	Disease	BOS	disease\N5S
3479	TOK	progression		progression\N5S
3480	TOK	or		or\CC
3481	TOK	death		death\N5S
---	DLE	(		=\DELIM
3482	TOK	to		to\P
3483	TOK	end		end\N5S
3484	TOK	of		of\P
3485	TOK	period		period\N5S
##	TAG	<num>
3486	TOK	2		2\X
##	TAG	</num>
---	DLE	)	EOS	=\DELIM
##	TAG	</head>
##	TAG	<head>
3488	TOK	Table	BOS	table\VMF6R66
##	TAG	<num>
3489	TOK	2	EOS	2\X
##	TAG	</num>
##	TAG	</head>
##	TAG	<head>
3491	TOK	Individual	BOS	individual\JA
3492	TOK	first		first\MOS
3493	TOK	outcome		outcome\N5S
3494	TOK	events		event\N5P
3495	TOK	at		at\P
3496	TOK	end		end\N5S
3497	TOK	of		of\P
3498	TOK	period		period\N5S
##	TAG	<num>
3499	TOK	2	EOS	2\X
##	TAG	</num>
##	TAG	</head>
##	TAG	<p>
##	TAG	<s>
3501	TOK	Number	BOS	number\N5S
3502	TOK	of		of\P
3503	TOK	patients		patient\N5P
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3504	TOK	Ritonavir	BOS	ritonavir\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
3506	TOK	Placebo	BOS	placebo\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3507	TOK	Deaths	BOS	death\N5P
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3508	TOK	AIDS	BOS	aid\VMFDRS3
---	DLI	-		=\DELIM
3509	TOK	defining		define\VMG----
3510	TOK	events		event\N5P
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3511	TOK	Total	BOS	total\JA
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
##	TAG	<name>
3512	TOK	Oesophageal	BOS	Oesophageal\N46
##	TAG	</name>
3513	TOK	candidosis		candidosis\N5P
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
##	TAG	<name>
3514	TOK	Kaposi	BOS	Kaposi\N46
##	TAG	</name>
3515	PGR	's		genmark\GENMARK
3516	TOK	sarcoma		sarcoma\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3517	TOK	Cytomegalovirus	BOS	cytomegalovirus\N5S
3518	TOK	retinitis		retinitis\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
##	TAG	<name>
3519	TOK	Pneumocystosis	BOS	Pneumocystosis\N46
##	TAG	</name>
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3520	TOK	Cytomegalovirus	BOS	cytomegalovirus\N5S
---	DLD	,		=\DELIM
3521	TOK	non		non\N5P
---	DLI	-		=\DELIM
3522	TOK	retinal		retinal\JA
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3523	TOK	Mycobacterium	BOS	mycobacterium\N5S
3524	TOK	avium		avium\N5S
3525	TOK	complex		complex\JA
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3527	TOK	Wasting	BOS	wasting\JA
3528	TOK	syndrome		syndrome\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3529	TOK	Lymphoma	BOS	lymphoma\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3530	TOK	Other	BOS	other\JA
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<head>
3531	TOK	Table	BOS	table\VMF6R66
##	TAG	<num>
3532	TOK	3	EOS	3\X
##	TAG	</num>
##	TAG	</head>
##	TAG	<head>
3534	TOK	Primary	BOS	primary\JA
3535	TOK	outcomes		outcome\N5P
3536	TOK	stratified		stratify\VMC----
3537	TOK	by		by\P
3538	TOK	baseline		baseline\N5S
3539	TOK	characteristics	EOS	characteristic\N5P
##	TAG	</head>
##	TAG	<head>
3541	TOK	Figure	BOS	figure\N5S
##	TAG	<num>
3542	TOK	3	EOS	3\X
##	TAG	</num>
##	TAG	</head>
##	TAG	<head>
3544	TOK	Overall	BOS	overall\JA
3545	TOK	survival		survival\N5S
---	DLE	(		=\DELIM
3546	TOK	to		to\P
3547	TOK	end		end\N5S
3548	TOK	of		of\P
3549	TOK	period		period\N5S
##	TAG	<num>
3550	TOK	3		3\X
##	TAG	</num>
---	DLE	)	EOS	=\DELIM
##	TAG	</head>
##	TAG	<head>
3552	TOK	Figure	BOS	figure\N5S
##	TAG	<num>
3553	TOK	4	EOS	4\X
##	TAG	</num>
##	TAG	</head>
##	TAG	<head>
3555	TOK	Mean	BOS	mean\VMF6R66
---	DLE	(		=\DELIM
3556	TOK	with		with\P
##	TAG	<name>
3557	TOK	SE		SE\N46
##	TAG	</name>
---	DLE	)		=\DELIM
3558	TOK	changes		change\N5P
3559	TOK	in		in\P
##	TAG	<name>
3560	TOK	CD4		CD4\N46
##	TAG	</name>
---	DLE	-		=\DELIM
3561	TOK	cell		cell\N5S
3562	TOK	count		count\VMF6R66
---	DLD	,		=\DELIM
##	TAG	<name>
3563	TOK	CD8		CD8\N46
##	TAG	</name>
---	DLE	-		=\DELIM
3564	TOK	cell		cell\N5S
3565	TOK	count		count\VMF6R66
---	DLD	,		=\DELIM
3566	TOK	and		and\CC
3567	TOK	plasma		plasma\N5S
##	TAG	<name>
3568	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
3569	TOK	1		1\X
##	TAG	</num>
##	TAG	<name>
3570	TOK	RNA		RNA\N46
##	TAG	</name>
3571	TOK	concentration	EOS	concentration\N5S
##	TAG	</head>
##	TAG	<p>
##	TAG	<s>
3572	TOK	Number	BOS	number\N5S
3573	TOK	of		of\P
3574	TOK	placebo		placebo\N5S
---	DLI	-		=\DELIM
3575	TOK	group		group\N5S
3576	TOK	patients		patient\N5P
3577	TOK	receiving		receive\VMG----
3578	TOK	open		open\JA
---	DLI	-		=\DELIM
3579	TOK	label		label\N5S
3580	TOK	ritonavir		ritonavir\N5S
3581	TOK	after		after\P
3582	TOK	period		period\N5S
##	TAG	<num>
3583	TOK	1		1\X
##	TAG	</num>
3584	TOK	given		give\VMC----
3585	TOK	in		in\P
3586	TOK	parentheses		parenthesis\N5P
3587	TOK	for		for\P
3588	TOK	visits		visit\N5P
3589	TOK	every		every\AG---S
##	TAG	<num>
3590	TOK	2		2\X
##	TAG	</num>
3591	TOK	months		month\N5P
3592	TOK	from		from\P
3593	TOK	month		month\N5S
##	TAG	<num>
3594	TOK	4		4\X
##	TAG	</num>
3595	TOK	onwards		onwards\DGA7
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	<s>
3596	TOK	Plasma	BOS	plasma\N5S
##	TAG	<name>
3597	TOK	HIV		HIV\N46
##	TAG	</name>
---	DLE	-		=\DELIM
##	TAG	<num>
3598	TOK	1		1\X
##	TAG	</num>
##	TAG	<name>
3599	TOK	RNA		RNA\N46
##	TAG	</name>
3600	TOK	for		for\P
3601	TOK	antiviral		antiviral\JA
3602	TOK	activity		activity\N5S
3603	TOK	subset		subset\N5S
3604	TOK	only		only\DGA7
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<head>
3605	TOK	Table	BOS	table\VMF6R66
##	TAG	<num>
3606	TOK	4	EOS	4\X
##	TAG	</num>
##	TAG	</head>
##	TAG	<head>
3608	TOK	Treatment	BOS	treatment\N5S
---	DLI	-		=\DELIM
3609	TOK	related		relate\VMC----
3610	TOK	adverse		adverse\JA
3611	TOK	events		event\N5P
---	DLE	(		=\DELIM
3612	TOK	in		in\P
3613	TOK	xxx		noanat\W
3614	TOK	of		of\P
3615	TOK	participants		participant\N5P
---	DLD	)		=\DELIM
3616	TOK	and		and\CC
3617	TOK	rates		rate\N5P
3618	TOK	of		of\P
3619	TOK	withdrawal		withdrawal\N5S
3620	TOK	from		from\P
3621	TOK	study		study\N5S
3622	TOK	medication	EOS	medication\N5S
##	TAG	</head>
##	TAG	<p>
##	TAG	<s>
3623	TOK	Symptom	BOS	symptom\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3624	TOK	Nausea	BOS	nausea\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3625	TOK	Vomiting	BOS	vomit\VMG----
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3626	TOK	Diarrhoea	BOS	diarrhoea\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3627	TOK	Weakness	BOS	weakness\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3628	TOK	Altered	BOS	alter\VMC----
3629	TOK	taste		taste\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
##	TAG	<name>
3630	TOK	Circumoral	BOS	Circumoral\N46
##	TAG	</name>
3631	TOK	paraesthesia		paraesthesia\N5S
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	<p>
##	TAG	<s>
3632	TOK	Total	BOS	total\JA
3633	TOK	withdrawn		withdraw\VMC----
---	DLD	.	EOS	=\DELIM
##	TAG	</s>
##	TAG	</p>
##	TAG	</div1>
